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ABSTRACT
The development of resistance is thought to be a major cause of treatment 
failure in cancer patients. Multidrug resistance is a form in which tumour cells 
develop cross-resistance to a range of natural products. This is commonly 
associated with increased expression of P-glycoprotein, which appears to act as a 
membrane efflux pump. The aims of the present studies were firstly to further 
characterise the mechanisms by which verapamil can sensitise resistant tumour 
cells to cytotoxic drugs, and secondly to investigate polyunsaturated fatty acids as 
an alternative means of sensitising drug resistant cell lines.
Verapamil was shown to increase the sensitivity to anthracyclines of 
multidrug resistant human ovary and breast cancer cell lines that express high 
levels of P-glycoprotein, thus confirming previous observations. Two other 
modulators, quinidine and bepridil, also sensitised these two cell lines. In 
addition, four human non-small cell lung cancer cell lines were sensitised by 
verapamil but only one of these lines expressed P-glycoprotein. Neither quinidine 
nor bepridil altered the drug sensitivity of any of these four cell lines. The results 
clearly demonstrate that verapamil can modulate drug resistance in the absence 
of P-glycoprotein.
The drug resistant ovarian and breast cell lines showed reduced 
anthracycline accumulation compared with the drug sensitive parental cell lines. 
Verapamil increased drug accumulation in the drug resistant cell lines by two fold, 
yet sensitised the cells by at least 11 fold. Intracellular drug distribution was 
studied in the multidrug resistant cell lines by autoradiography. This method 
allowed quantification of drug associated with the nucleus and the cytoplasm. 
Most of the anthracycline daunorubicin was located in the nucleus in both drug 
sensitive and drug resistant cell lines. However, the ratio of nuclear to 
cytoplasmic grain counts was greater in the sensitive than in the resistant cell 
lines. Verapamil caused an increase in grain counts and a shift in the nuclear to 
cytoplasmic grain count ratio in the drug resistant cells to a level approaching that 
in the drug sensitive cell lines. It is concluded that verapamil sensitises cells not 
only by increasing the amount of drug accumulated but also by redistributing drug 
within the cell to the potential site of action of the anthracyclines, the nucleus. 
Furthermore, such effects on drug distribution may not be related to P- 
glycoprotein expression and this could account for the activity of verapamil in P- 
glycoprotein negative cell lines.
Studies of intracellular drug distribution led to the observation of a marked 
heterogeneity in drug accumulation and morphology in the parental and drug 
resistant ovarian cell lines. Clonal cell lines were isolated from the ovarian lines. 
For the drug sensitive cell line the heterogeneity in drug accumulation was shown 
to be caused by differences in cell size, such that intracellular drug concentrations 
were comparable. Two clonal cell lines derived from the resistant cell line 
maintained their multidrug resistant phenotype for at least 20 weeks, even in the 
absence of exposure to doxorubicin, the agent used to select and maintain the
resistant cell line. In contrast, four other clonal cell lines derived from the 
resistant cell line lost their resistant phenotype when cultured over a period of 
time in the absence of doxorubicin. This loss of resistance correlated with loss 
of expression and function of P-glycoprotein but both resistance and P- 
glycoprotein expression were restored by a single exposure to doxorubicin. Thus 
it appears that development of drug resistance in vitro by chronic exposure to 
doxorubicin can be associated with the selection of a number of different 
resistance phenotypes which can be maintained within a mixed population 
provided that the selection pressure is continued.
Growth of cells in vitro in the presence of fatty acids can alter the 
membrane composition and hence fluidity and permeability. Exposure of both 
doxorubicin and cisplatin resistant human ovarian cell lines to non-toxic 
concentrations of polyunsaturated fatty acids either before or during exposure to 
cytotoxic drugs did not modulate drug sensitivity. However, both gamma linolenic 
acid and eicosapentaenoic acid were cytotoxic alone even to drug resistant cell 
lines. Furthermore, isobologram analysis was used to demonstrate that this 
toxicity was additive with that of the cytotoxic drugs. Since the fatty acids have 
been given to patients without undue side effects these observations suggest that 
this additive toxicity to tumour cells could be exploited in the clinic.
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CHAPTER 1
General Introduction
Chemotherapy has an important role in cancer treatment. With the 
introduction of more effective drugs and the optimisation of therapeutic strategies, 
clinical responses have steadily improved in patients with malignancies including 
Hodgkin’s disease, testicular cancer and lymphocytic leukaemia (De Vita, 1982). 
Some encouraging results of treatment have also been achieved in patients with 
other common malignancies such as ovarian cancer, breast cancer and lung 
cancer. Unfortunately, the successes of chemotherapy are inevitably 
overshadowed by the eventual relapse of patients who initially responded. 
Implementation of the same regimen seldom results in a second remission due to 
the emergence of drug resistance. To make matters worse, in most cancers the 
development of resistance to a single drug or combination is often coupled with 
the emergence of cross resistance to a wide variety of other antineoplastic agents 
to which the tumour cells have not been exposed. This type of induced cross­
resistance is termed ‘acquired’ as opposed to ‘de novo’ resistance which is used 
for tumours such as colon cancer which are resistant from the outset (Moscow 
and Cowan, 1988).
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Anthracyclines
Daunorubicin was the first anthracycline to be isolated and recognised to 
have anti-tumour activity (Arcamone, 1985), particularly against leukaemias (Gale 
& Foon, 1987). Subsequently doxorubicin was isolated and shown to have a wider 
range of anti-tumour activities (Arcamone, 1985). It is now clear that doxorubicin 
has the widest spectrum of all chemotherapeutic agents and is highly effective in 
a number of tumour types (Weiss et al, 1986). Doxorubicin and daunorubicin are 
identical except that daunorubicin has an acetyl group at the C-9 position of the 
anthracycline ring and doxorubicin has a hydroxyacetyl group at this position (see 
Chapter 3 Fig. 1 for structures). This small difference results in enhanced 
lipophilicity of daunorubicin and more rapid metabolism and elimination (Gewirtz 
& Yanovich, 1987). Although widely used in chemotherapy the activity of 
anthracyclines is limited by cardiotoxicity. As a result a large number of 
analogues have been synthesised and are currently undergoing preclinical and 
clinical evaluation (Mross, 1991).
Although they have been in clinical use for many years the exact 
mechanism by which anthracyclines exert their cytotoxicity is as yet unknown. 
Anthracyclines exert multiple effects on cells. Those which have been considered 
the most important in killing tumour cells are: (1) intercalation into DNA; (2) 
inhibition of topoisomerase II; (J) interaction with the cell membrane and (4) free 
radical formation (Gianni et al, 1983; Powis, 1987).
It has generally been assumed that the binding of anthracyclines to DNA
occurs via intercalation of anthraquinone ring into the DNA helix. However, the 
possible existence of ternary complexes of doxorubicin, DNA and iron has also 
been discussed (Eliot et al, 1984). Topoisomerase II is an essential nuclear 
enzyme involved in DNA replication (Liu, 1989; Wang, 1985). Both the 
epipodophyllotoxins and the anthracyclines interfere with the activity of 
topoisomerase II (Beck & Danks, 1991). Although it is not known how drugs 
which inhibit this enzyme cause cell death it has been postulated that a stable 
complex is formed between the enzyme and DNA in the presence of the drug 
(Shen et al, 1989).
Direct cell membrane action is hypothesised as another cytotoxic effect of 
anthracyclines. This concept is supported by several observations which 
demonstrate that anthracyclines can exert their cytotoxic effect without entering 
cells (Tokes et al, 1982; Tritton & Yee, 1982). The interaction of anthracyclines 
with cell membranes can also result in changes in membrane lipid composition, 
membrane fluidity and permeability (Okano et al, 1984) as well as inhibition of 
plasma membrane enzymatic activities (Sun et al, 1984). It is also clear that free 
radical formation catalysed by intracellular enzymes, can be responsible for DNA 
strand breaks as well as cytoplasmic damage. The semiquinone free radical 
formed by reduction of the anthracycline quinone moiety can in turn react with 
molecular oxygen to yield superoxide anion and subsequently hydrogen peroxide 
and hydroxyl radical. These can then cause the membrane lipid peroxidation and 
DNA damage. Generation of free radicals is thought to be responsible for the 
cardiotoxicity of the anthracyclines (Davies & Doroshow, 1986; Doroshow &
Davies, 1986). Although cardiotoxicity is a major factor in determining the 
maximum tolerated dose of the anthracyclines, the observation that complete 
responses can be achieved suggests that the development of resistance is the key 
factor limiting their clinical efficacy (Kaye & Merry, 1985).
Multidrug drug resistance
Investigations on the cellular mechanisms of drug resistance have relied 
extensively on the use of model systems in vitro. Continuous cell lines selected 
for resistance to chemotherapeutic agents are derived by exposing cells chronically 
to a stepwise increasing concentration of a single drug. When the drug used is 
an anthracycline, Vinca alkaloid, podophyllotoxin or colchicine, resistance is 
induced not only to the selecting drug but also to the other members of this group 
of high molecular weight natural product amphipathic drugs (Biedler & Riehm, 
1970; Dano, 1972; Kessel et al, 1968). In general, multidrug resistant cells are not 
cross resistant to cisplatin, bleomycin, alkylating agents or antimetabolites (Schurr 
et al, 1989; Supino et al, 1986; Twentyman et al, 1986a & b).
Although not universally seen, the most common changes observed in 
MDR cell lines are (7) a reduction in steady-state cellular drug accumulation 
(Beck et al, 1983; Fojo et al, 1985; Riehm & Biedler, 1971; Tsuruo et al, 1982; 
Twentyman et al, 1986b); (2) an increase in drug extrusion rate (Dano, 1973; Fojo 
et al, 1985; Inaba et al, 1979), and (3) a hyperexpression of a specific membrane
glycoprotein with a molecular weight of 170,000 dalton known as P-glycoprotein 
(Juliano & Ling 1976; Kartner et al, 1983a & b; Ma et al, 1987). The latter is 
associated with both an amplification of the mdr gene family, including mdrl 
which encodes P-glycoprotein (Bourhis et al, 1989; Keith et al, 1990; Riordan et 
al, 1985a; Van der Bliek et al, 1986, 1988) and an increased expression of the 
corresponding mRNA (Reeve et al, 1989; Scotto et al, 1986; Shen et al, 1986).
MDR cells expressing P-glycoprotein exhibit reduced intracellular drug 
accumulation and increased drug extrusion, and interference with P-glycoprotein 
increases drug accumulation (Broxterman et al, 1988; Hamada & Tsuruo, 1986; 
Rittmann-Grauer et al, 1990). This led to the suggestion that P-glycoprotein may 
actively exclude xenobiotics from resistant cells, resulting in lower intracellular 
drug accumulation and reduced toxicity (Juliano & Ling, 1976; Kartner et al, 
1983a & b; Ling et al, 1983).
Direct evidence in support of this causal role for the P-glycoprotein in 
MDR has come from the isolation of complementary DNA for mouse (Gros et 
al, 1986b) and human (Chen et al, 1986) P-glycoprotein and from the subsequent 
transfection experiments. Transfection and expression of cloned complementary 
DNA encoding P-glycoprotein into drug sensitive NIH 3T3 cells is able to confer 
the MDR phenotype (Croop et al, 1987; Gros et al, 1986a; Ueda et al, 1987). 
Moreover, a single spontaneous mutation in mdrl gene leading to substitution of 
glycine to valine at position of 185 of P-glycoprotein results in preferential 
resistance of an MDR variant to colchicine (Choi et al, 1988).
The deduction of the full length of P-glycoprotein primary sequence
predicts a protein 1280 amino acids long and consisting of two homologous halves 
connected by a 60 amino acid sequence (Chen et al, 1986; Gerlach et al, 1986; 
Gros et al, 1986b). Comparison of the deduced P-glycoprotein primary sequence 
with other available data has subsequently shown that the hydrophillic regions on 
each of two homologous halves share striking similarity with a class of bacterial 
transport proteins (Croop et al, 1987; Gros et al, 1986b; Ueda et al, 1987). 
Further analysis of the predicted structure of P-glycoprotein suggests that each 
half of the protein contains six potential transmembrane regions. This implies 
that the P-glycoprotein molecule can span the membrane 12 times to form a 
transmembrane configuration characteristic of a channel-like structure. Moreover, 
a highly conserved hydrophillic region, located on the predicted cytoplasmic 
domain, has the characteristics of an ATP-binding site (Chen et al, 1986; Gerlach 
et al, 1986; Gros et al, 1986b) and P-glycoprotein has been shown to have ATPase 
activity (Hamada & Tsuruo, 1988a & b). Thus the structure of the P-glycoprotein 
is consistent with a role for P-glycoprotein as an ATP-driven active drug efflux 
pump. In support of this hypothesis are the findings showing that ATP binds 
specifically to P-glycoprotein (Cornwell et al, 1987b) and the protein itself has 
ATPase activity (Hamada & Tsuruo, 1988a & b). Furthermore, the use of 
photoaffinity labelled Vinca alkaloids showed that drugs in the MDR category are 
able to bind directly to the P-glycoprotein.
P-glycoprotein has been predicted to have two binding sites for azidopine, 
a photoaffinity labelling agent (Bruggemann et al, 1989). Further evidence in 
support of the speculation that P-glycoprotein acts as a ‘hydrophobic vacuum
cleaner’, binding natural antineoplastic products and removing them from resistant 
cells, comes from the competition binding studies using photoaffinity labelling 
technique. In these experiments a range of MDR-related agents exhibited higher 
affinity to the membrane vesicles from P-glycoprotein hyperexpressing resistant 
cells than to those from wild type sensitive cells. The binding of these drugs to 
the membrane preparations was ATP-dependent (Cornwell et al, 1986a & b; 
Horio et al, 1988; Naito & Tsuruo, 1989).
Atypical multidrug resistance
Although the majority of multidrug resistant cell lines have been shown to 
overexpress P-glycoprotein it has become apparent that induction of drug 
resistance in vitro can give rise to cell lines with the characteristic cross-resistance 
phenotype of MDR but without overexpression of P-glycoprotein (Beck et al, 
1987; Cass et al, 1989; Coley et al, 1991a; Mirski et al, 1987). Beck (1989) has 
used the term ‘atypical MDR’ to describe such cell lines. In many cases 
resistance is associated with decreased expression of topoisomerase II. On the 
whole such cell lines do not show reduced drug accumulation (Danks et al, 1987; 
Harker et al, 1989), but there are exceptions which may be associated with an 
alternative drug efflux mechanism (Mirski et al, 1987; Taylor et al, 1991; 
Twentyman et al, 1986b; Zijlstra et al, 1987a).
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Expression of P-glycoprotein in human tissues and tumours
Identification of P-glycoprotein in vitro and the subsequent isolation of the 
gene and protein allowed the development of cDNA probes for mdr\ mRNA and 
monoclonal antibodies specific for the protein (Juliano & Ling, 1976; Hamada & 
Tsuruo, 1986; Kartner et al, 1985; Riordan et al, 1985b; Roninson et al, 1986; Van 
der Bliek et al, 1986). It is therefore possible to detect P-glycoprotein expression 
both at the level of mRNA by Northern analysis and at the level of the protein 
by both immunocytochemistry and Western analysis. One of the most important 
findings has been the detection of P-glycoprotein in a number of normal tissues 
in humans. These include adrenal gland, kidney, liver and large intestine. One 
of the advantages of immunohistochemistry is that it allows precise location of the 
marker expression. P-glycoprotein was shown to be expressed on the luminal 
surface of the kidney brush border, on the mucosal surface of large intestine and 
on the bile canalicular surface of hepatocytes. These locations suggest a role for 
P-glycoprotein in protecting against exogenous toxins and, possibly, in removal of
such toxins from the body (Thiebault et al, 1987).
There have been a large number of reports of expression of P-glycoprotein 
in human tumours. Goldstein et al (1989) analysed more than 400 human 
tumours by mRNA slot blot. They showed expression in untreated tumours 
derived from colon, kidney, adrenal gland and liver. All of these tumour types 
are characteristically resistant at presentation and are derived from tissues with 
intrinsic expression of P-glycoprotein. Although this suggests an interesting link
it should be stressed that some of the mRNA analysed will originate from 
contaminating normal tissue in the tumour biopsy. Expression was also detected 
in carcinoid tumours, pancreatic tumours and cell lines established from non-small 
cell lung cancers. Ma et al (1987) showed expression of P-glycoprotein in acute 
non-lymphoblastic leukaemia and demonstrated a correlation between the 
proportion of blast cells that stained positive for P-glycoprotein and disease 
progression. Some tumours which do not appear initially to express P- 
glycoprotein have been found to express P-glycoprotein at relapse following 
chemotherapy, e.g., ovary (Bourhis et al, 1989), acute myeloid leukaemias (Sato 
et al, 1990) and multiple myeloma (Dalton et al, 1989). A number of reports have 
noted expression of P-glycoprotein in untreated breast tumours (Keith et al, 1990; 
Schneider et al, 1989; Wishart et al, 1990). Wishart et al (1990) used 
immunocytochemistry and were able to demonstrated P-glycoprotein in the 
majority of tumours although expression was heterogeneous. More importantly 
they noted expression in the stromal cells as well as in the epithelial cells of the 
tumour. Furthermore, Weinstein et al (1991) demonstrated preferential 
expression of P-glycoprotein in areas of invasive growth of colon tumours. They 
suggest that P-glycoprotein expression may correlate with the degree of 
malignancy of a tumour but it is also possible that the P-glycoprotein has a role 
in invasion and metastasis.
There have been a few attempts to correlate P-glycoprotein expression with 
response to treatment (Pirker et al, 1991; Salmon et al, 1989). The most 
convincing of these studies was that of Chan et al (1990) who developed the
methodology to detect P-glycoprotein by immunohistochemistry in formalin fixed 
paraffin embedded tissue. This allowed a retrospective study of childhood 
sarcoma over a nine year period. They were able to demonstrate a clear 
correlation between P-glycoprotein expression and response to treatment and 
survival.
Resistance modulators
A number of agents are able to sensitise MDR cell lines to cytotoxic drugs. 
These resistance modulators belong to various groups of drugs which by 
themselves are non-cytotoxic. The most potent show some structural similarity 
in that they are typically hydrophobic molecules featuring two planar aromatic 
rings and a tertiary basic nitrogen atom with a positive charge at physiological pH 
(Rothenberg & Ling, 1989). The calcium channel blocker verapamil was the first 
such agent identified (Tsuruo et al, 1981). Verapamil was shown to sensitise 
vincristine resistant P388 leukaemia cells to both vincristine and vinblastine and 
sensitisation was accompanied by increased drug accumulation.
Following this discovery, various types of human (Cass et al, 1989; Fojo et 
al, 1985; Rogan et al, 1984; Tsuruo et al, 1983a & b; Twentyman et al, 1986a; 
Willingham et al, 1986) and animal (Chatterjee et al, 1990; Kessel & Wilberding, 
1985; Ramu et al, 1983b; Supino et al, 1988; Twentyman et al, 1990) MDR cell 
lines have been shown to be sensitised to a number of MDR drugs in the
presence of verapamil. In addition, numerous other agents have been identified 
as active in drug resistance modulation in experimental models, including bepridil 
(Schuurhuis et al, 1987), quinidine (Tsuruo et al, 1984), perhexiline maleate 
(Ramu et al, 1984a), cyclosporins (Slater et al, 1986; Twentyman, 1988), reserpine 
(Beck et al, 1988), tamoxifen (Ramu et al, 1984b; Chatterjee & Harris, 1990) and 
other related compounds (Cole et al, 1989; Dusre et al, 1989; Jamali et al, 1989; 
Kessel, 1986). In most cases sensitisation is accompanied by increased drug 
accumulation and it is thought that resistance modulators act via inhibition of the 
drug efflux mechanism associated with P-glycoprotein (Rogan et al, 1984; Tsuruo 
et al, 1983a). A number of photoaffinity analogs of both cytotoxic drugs 
associated with the MDR phenotype and resistance modulators have been shown 
to bind to P-glycoprotein (Beck et al, 1988; Busche et al, 1989; Cornwell et al, 
1986a & b; Foxwell et al, 1989; Qian & Beck, 1990; Safa et al, 1987 & 1989; Safa, 
1988; Yang et al, 1988). The resistance modulators can displace the cytotoxic 
drugs from P-glycoprotein but not a photoaffinity analog of ATP suggesting that 
modulators interfere with drug binding to the pump and not the energy supply to 
the pump (Cornwell et al, 1987a & b).
Resistance modulation in the clinic
Following the identification of P-glycoprotein in several human tumour 
types there have been a number of clinical trials of resistance modulators. An
initial trial of verapamil in addition to chemotherapy for ovarian cancer failed to 
show an improved response (Ozols et al, 1987). However this trial identified 
cardiotoxicity as the major dose limiting factor in the use of verapamil. As a 
result, the plasma levels achieved in patients are between 3 and 12 times lower 
than the most effective concentration in vitro (Cairo et al, 1989; Dalton et al, 1989; 
Kerr et al, 1986). Although Dalton et al (1989) showed promising results in 
patients with multiple myeloma treated with verapamil in addition to 
chemotherapy the study was far too small to draw any real conclusions about the 
effectiveness of modulators in the clinic. Similarly, Sonneveld & Nooter (1990) 
reported the activity of cyclosporin-A as a modulator in the clinic based on 
observations on a single patient.
Thus there is little evidence as yet that resistance modulators can be 
effective in patients. Verapamil is clearly not the most effective agent due to its 
cardiological activity and there is a need to identify more suitable agents for 
clinical use. This can be done either by trial and error with modulators identified 
in vitro or by obtaining a clearer understanding of the mechanism of action of 
modulators in order to design better agents.
Aims of the thesis
The main aims of these studies can be summarised as follows:
(1) to characterise verapamil as a resistance modulator
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(2) to determine whether verapamil affects intracellular drug distribution
(2) to find alternative means of overcoming drug resistance
Lay-out of the thesis
Each chapter begins with a self-contained Introduction and therefore full 
details of the rational behind the various individual stages of the work will not be 
discussed here.
A number of observations have indicated that verapamil can sensitise cells 
to cytotoxic drugs by mechanisms other than inhibition of P-glycoprotein. Cole 
et al (1989) reported that verapamil could sensitise a doxorubicin resistant cell 
line that does not express P-glycoprotein. Furthermore, several studies have 
indicated a discrepancy between the magnitude of the effects of verapamil on 
drug sensitivity and its effects on drug accumulation (Ford et al, 1991; Kessel & 
Wilberding, 1984; Rogan et al, 1984). Because of these findings, the experimental 
work of the thesis begins with a comparison of three different resistance 
modulators using a panel of cell lines that includes both P-glycoprotein positive 
and negative cell lines (Chapter 2). The results clearly establish verapamil as a 
modulator with a broad spectrum of activity that extends to cell lines that do not 
express P-glycoprotein.
In Chapter 3 evidence is presented that verapamil can alter the distribution 
of drug within multidrug resistant cell lines. During the course of this work a
marked morphological heterogeneity was observed in both the parental cell line 
and the multidrug resistant subline used for these experiments. This 
heterogeneity stimulated a study of clonal populations derived from these cell 
lines. Chapter 4 describes differences in the stability of P-glycoprotein expression 
and the drug resistance phenotype for some of these clones.
It was clear that drug sensitivity could be affected by changes in 
intracellular drug distribution. This suggested that it might be possible to alter 
drug sensitivity by changing the composition of the cell membranes. Furthermore, 
Timmer-Bosscha et al (1989) have shown that docosahexaenoic acid can sensitise 
a cisplatin resistant cell line to cisplatin and demonstrated that the fatty acid was 
incorporated into the cell membrane. Chapter 5 describes an attempt to 
modulate both doxorubicin and cisplatin sensitivities with two polyunsaturated 
fatty acids, gamma linolenic acid and eicosapentaenoic acid. Although 
modulation was not observed, these agents were found to exhibit interesting 
additive toxicity which could be explored in the clinic.
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CHAPTER 2
General methods and characterisation of verapamil as a 
resistance modulator
Introduction
Although verapamil was the first agent identified that can overcome 
multidrug resistance associated with P-glycoprotein overexpression (Tsuruo et al, 
1981), a number of other compounds have since been identified that share this 
property (Stewart & Evans, 1989). However, verapamil remains one of the most 
interesting resistance modulators in the laboratory since it has also been shown 
to be active in cell lines that express the multidrug resistance phenotype in terms 
of cross resistance patterns but do not express P-glycoprotein (Cole et al, 1989; 
Coley et al, 1991a). This property of verapamil has been ascribed either to effects 
on membrane trafficking (Sehested et al, 1987a & b) or to the presence of an 
alternative drug efflux pump (Reeve et al, 1990). It is not known whether 
verapamil is unique in this activity since there have been few comparative studies 
of resistance modulators.
One of the major aims of this thesis is to characterise the activity of 
verapamil in multidrug resistant cell lines in order to determine whether
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sensitisation is due solely to effects on drug accumulation. Three pairs of cell 
lines were available within the Department of Medical Oncology for use in these 
studies. Only two of these were chosen for use since the third, a human small-cell 
lung cancer cell line NCI-H69 and a doxorubicin resistant subline H69LX10 are 
non-adherent cell lines with indistinct cytoplasm. This latter pair is clearly not 
suitable for studies of intracellular drug distribution. The human ovarian cancer 
cell line A2780 and the in vitro derived doxorubicin resistant subline were selected 
for use in the majority of experiments. The latter cell line, 2780AD, expresses 
high levels of P-glycoprotein (Sugawara et al, 1988) and has been shown to be 
sensitised to doxorubicin by verapamil (Plumb et al, 1990; Rogan et al, 1984). In 
contrast the parent cell line A2780 does not express P-glycoprotein (Sugawara et 
al, 1988; R. Brown, personal communication) and is not sensitised by verapamil 
(Plumb et al, 1990). The human breast cancer cell line MCF7 and the 
doxorubicin resistant subline MCF7/Adr were also used for comparison. These 
cell lines share similar properties to those described for the ovarian cell lines, 
including their P-glycoprotein status, except that MCF7/Adr is highly resistant 
(ID50 for doxorubicin 21 \iM, Plumb et al, 1990) and thus requires large quantities 
of drug for cytotoxicity assays.
The aim of the experiments described in this chapter was to characterise 
the effects of verapamil on drug sensitivity and drug accumulation in the two pairs 
of multidrug resistant cell lines. Both doxorubicin and daunorubicin were used. 
Although doxorubicin was the main drug of interest in view of its wide range of 
antitumour activity in the clinic, supplies of radioactively labelled doxorubicin
were limited and expensive. Daunorubicin was therefore included in order to 
determine whether this anthracycline could be used to answer the same questions. 
In addition four non-small cell lung cancer cell lines were included in the study. 
Previously, a number of human non-small cell lung cancer cell lines were shown 
to demonstrate a drug sensitivity profile similar to that of multidrug resistant cell 
lines (Merry et al, 1987). None of these cell lines had been exposed to cytotoxic 
drugs in vitro and it was not known whether any of them express P-glycoprotein. 
However, this form of lung cancer is usually resistant to chemotherapy at 
presentation (Minna et al, 1985). Four of the non-small cell lung cancer cell lines 
have now been characterised for P-glycoprotein expression by detection of mRNA 
in the Department of Medical Oncology. One of the cell lines WIL has low levels 
of mdrl mRNA but the other three have very low if any expression of mdrl 
mRNA (R. Brown, personal communication). Since the analysis was carried out 
by Northern blots it is not possible to state that these lines do not express mdrl 
mRNA as a more sensitive technique such as the polymerase chain reaction could 
possibly detect the mRNA (Barrand & Twentyman, 1992). Furthermore, P- 
glycoprotein could not be detected by immunocytochemistry in any of the four 
non-small cell lung cancer cell lines. Merry et al (1987) had shown that some of 
these cell lines could be sensitised to etoposide, vincristine and doxorubicin by 
verapamil. These cell lines were therefore included in the study in order to 
determine whether the activity of verapamil was related to the level of expression 
of P-glycoprotein. Since it was possible that verapamil was not acting via P- 
glycoprotein in 3 of the non-small cell lung cancer cell lines two other resistance
modulators were included for comparison. Quinidine was used since it has been 
shown that plasma levels of 6 pM can be achieved in patients and is therefore a 
potential candidate for clinical trials (Jones et al, 1990; Tsuruo et al, 1984). 
Whilst verapamil is a calcium channel blocker quinidine is thought to exhibit 
cardiological activity through a general membrane perturbation (Surewicz & 
Jozwaik, 1983). Bepridil is a calcium channel blocker like verapamil and has 
been shown to modulate drug resistance (Schuurhuis et al, 1987). Although it is 
not in clinical use in this country it has been used in France and plasma levels of 
4 pM can be achieved in patients (S.B. Kaye, personal communication).
In these experiments and throughout this work drug sensitivity was 
determined by a tetrazolium dye based microtitration assay. This assay was 
developed and characterised with the Department of Medical Oncology and has 
been shown to give identical results to a standard clonogenic assay (Plumb et al, 
1989). Cell lines A2780 and 2780AD have very poor plating efficiencies in 
clonogenic assays (about 15%) and produce very small colonies. Both perform 
well in the microtitration assay. A second advantage of the latter assay is that 
large numbers of cytotoxicity tests can be performed at any one time under 
standardised conditions. This is important where direct comparisons are made 
between cell lines and in experiments where modulators are used.
In addition to presenting results on the characterisation of verapamil and 
to a lesser extent certain other agents as resistance modifiers in various cells, this 
chapter also gives details of the general methods used throughout the thesis.
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Materials and Methods
Cell lines
The human ovarian cancer cell line A2780 and the subline made resistant 
in vitro to doxorubicin (2780AD), were obtained from Dr. R. F. Ozols (Fox Chase 
Cancer Centre, Philadelphia, U.S.A.). The human breast cancer cell line MCF7 
and its doxorubicin resistant subline MCF7/Adr were kindly provided by Dr. K. 
Cowan (National Cancer Institute, Bethesda, U.S.A.). Both 2780AD and 
MCF7/Adr express high levels of P-glycoprotein (Fairchild et al, 1987; Sugawara 
et al, 1988).
The two of four human non-small cell lung cancer cell lines used, a 
bronchiolo-alveolar carcinoma cell line A549 and a squamous carcinoma cell line 
SK-MES, were from the American Type Tissue Culture Collection (ATCC, 
U.S.A.). The adenocarcinoma cell line WIL was obtained from the Ludwig 
Institute (Sutton, U.K.) and the squamous lung carcinoma cell line L-DAN was 
established in the CRC Department of Medical Oncology, University of Glasgow, 
U.K.). Cell lines A549, L-DAN and SK-MES express very low levels of mdrl 
mRNA by Northern blot analysis. The levels in WIL are about 4 times higher 
than in the 3 other non-small cell lung cancer lines but are only one tenth of the 
levels observed in the human small cell lung cancer line H69LX10 which is 60 
fold resistant to doxorubicin (Plumb et al, 1990; R. Brown, personal 
communication). P-glycoprotein cannot be detected by immunocytochemistry in
any of the 4 non-small cell lung cancer cell lines.
Culture media
The ovarian and breast cancer cell lines were grown in Roswell Park 
Memorial Institute 1640 (RPMI 1640) medium (Northumbria Biologicals, 
Cramlington, Northumberland, U.K.) supplemented with glutamine (2 mM) and 
foetal calf serum (10%). For the ovarian cell lines insulin (0.25 units/ml) was 
also added.
The non-small cell lung cancer cell lines were grown in a mixture (50:50) 
of Ham’s F10 (Northumbria Biologicals, Cramlington, Northumberland, U.K.) and 
Dulbecco’s Modified Eagles Medium (Life Technologies Ltd., Paisley, U.K.) 
supplemented with glutamine (2 mM) and foetal calf serum (10%).
The media were prepared from 10 x concentrated stock solutions. It was 
buffered by addition of sodium bicarbonate (0.075%) and equilibrated with C 0 2 
(2% in air).
Culture conditions
All the cell lines grew as monolayer cultures. They were maintained in 
exponential phase of growth in 75cm2-flasks (J. Bibby Science Products Ltd,
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Staffordshire, U.K.) or in 25cm2-flasks (Nunclon, Life Technologies Ltd., Paisley, 
U.K.). Cells were subcultured at one week intervals. The monolayer of cells was 
exposed to trypsin (0.25%, Life Technologies Ltd., Paisley, U.K.) in the presence 
of ethylenediaminetetraacetic acid (EDTA, 1 mM, BDH, Poole, U.K.) in Ca2+ 
and Mg2+ free phosphate buffered saline (Dulbecco’s A, PBS) for 30 seconds. 
The solution was removed and the monolayer incubated at 37°C for 5 minutes. 
Trypsin was inactivated and the cells collected by addition of 10 ml of culture 
medium. Cell number was determined with an electronic counter (Coulter Model 
ZB1, Coulter Electronics Ltd., Luton, Beds, U.K.) and cells were plated into new 
flasks at a density of 5 x 105/25cm2 flask or 2 x 106/75cm2 flask. Flasks were 
equilibrated with C 0 2 (2% in air) and sealed. Cultures were fed with fresh 
medium at intervals of 2-3 days.
For the doxorubicin resistant cell lines resistance was maintained by 
regular exposure to the selecting agent. Cell line 2780AD was grown constantly 
in the presence of doxorubicin (2 pM). Cell line MCF/Adr was exposed to 
doxorubicin (10 pM) for 24 hours once every six weeks. Both cell lines were 
grown in the absence of drug for at least 5 days prior to experiments so that 
cellular doxorubicin content was at minimal levels.
Mycoplasma testing
All the cell lines were examined once a month for mycoplasma
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contamination by the Hoechst staining methodj (Chen, 1977).
Maintenance of cell stocks
Stocks of all cell lines were held in liquid nitrogen. Cells were maintained 
in culture for 3 months and then replaced with fresh cells from the frozen stocks. 
This reduced variability due to maintenance in continuous culture and reduced 
the risk of cross contamination of cell lines.
Monolayer cultures were harvested with trypsin, collected into a sterile 
universal container (Bibby Sterilin Ltd., Stone, Staffs, U.K.) and centrifuged for 
5 minutes at 200 g. The pellet was resuspended at a density of about 5 xl06/ml 
in culture medium containing dimethyl sulphoxide (10%, Merck, Thornlibank, 
Glasgow, U.K.). This suspension was divided into 1 ml cryotubes (Nunclon, Life 
Technologies Ltd., Paisley, U.K.) and frozen at a rate of 1°C per minute in a 
insulated container in a freezer at -70°C. After at least 4 hours they were 
transferred into liquid nitrogen.
When required, an ampoule was removed and placed in warm water 
(37°C). The cell suspension was transferred into a 25 cm2 flask and 5 ml of 
culture medium added. The cells were equilibrated with C 0 2 (2%), the flasks 
sealed and incubated at 37°C for 24 hours. The medium was then replaced with 
fresh medium and the cells allowed to grow. They were passaged twice before
f
use in experiments.
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Measurement of cell volume
When necessary cell size was determined with an electronic particle 
counter. Calibration of the Coulter counter (Model Industrial D; Coulter 
Electronics Ltd., Luton, Beds, U.K.) for cell sizing was carried out with standard 
polystyrene divinyl benzene latex beads (P.D.V.B. Latex, Coulter Electronics Ltd., 
Luton, Beds, U.K.) using a half-count technique (Section 6.1, Reference Manual 
for the Coulter Counter Model D, issue A: 1984). The threshold (t), the 
attenuation (A) and the aperture (I) were determined for a given size of latex 
beads. The calibration constant (Kj) was calculated by the following equation:
Kd = d /  ( t x I x A  )1/3 
where d is the known mean diameter of the P.D.V.B. particles in pm.
The cell sizing was done by determining t, I and A for each cell line. The 
mean diameter of a single cell was derived from the above formula and the 
volume of a cell assuming a spherical shape was calculated as 1/6 7td3 in pm3.
Determination of doubling time
The doubling time of a cell line was determined from cell counts of cells 
in optimal culture conditions. Cells were seeded in 1 ml of culture medium into 
24-well plates (Nunclon, Life Technologies Ltd., Paisley, U.K.) at a density of 104 
cells per well and grown at 37°C in a humidified atmosphere of 2% C 0 2 in air.
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Cells in 3 wells were trypsinised and counted daily and the medium was replaced 
daily. Cell doubling time was determined from the slope of the exponential 
growth phase obtained from a plot of log cell number against time in days.
Cytotoxicity assay
Drug sensitivity was determined by a tetrazolium dye based microtitration 
assay (Mosmann, 1983) which was further developed and optimised in the 
department (Plumb et al, 1989). In this assay cells in the exponential phase of 
growth are exposed to drug for a fixed time period and then allowed to grow in 
drug free medium for 2-3 cell doublings. Finally, cell number is determined 
indirectly by the reduction of tetrazolium dye, 3-(4,5-dimethylthiazo(-2-yl)-2,5-di- 
phenyletetrazolium bromide (MTT, Sigma Chemical Company, Poole, U.K.), by 
live but not dead cells to a water-insoluble purple formazan product. Under 
appropriate conditions the absorbance of the reduced dye is proportional to the 
biochemically viable cell number. It is a rapid and reproducible assay which is 
ideally suited to this type of project and the results agree well with those of a 
standard clonogenic assay (Plumb et al, 1989).
Cells were plated out into 96-well microtitre plates (12 x 8 wells, Linbro, 
ICN Biomedicals Ltd., High Wycombe, Bucks, U.K.) in 200 \d of medium at a 
concentration of 5 x 102 to 1 x 103 cells per well and grown at 37°C for 2-3 days 
in a humidified atmosphere of 2% C 0 2 in air. The first and last rows of 8 wells
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on the plate contained medium only. Cells were then exposed to drug for 24 
hours unless stated otherwise. A serial dilution of drug was prepared (usually 1:4) 
to give a total of 8 concentrations such that the ID50 of the cell line was in the 
middle of the range. Four replicate wells were used for each drug concentration 
and cells in the second and eleventh rows of eight wells were fed with drug-free 
medium only. When a resistance modulator was used the drug was prepared at 
twice the final concentration and diluted 1:1 with medium or medium containing 
the modulator at twice the final concentration before addition to the cells. For 
these experiments the plate was divided into 2 such that the top 4 wells received 
drug alone while the bottom 4 contained drug plus modulator. Modulator alone 
was added to the second and eleventh rows in the bottom half of the plate. After 
24 hours, the medium and drugs were removed by needle aspiration and cells fed 
with drug free medium daily for 3 days. They were then fed with 200 pi of fresh 
medium containing Hepes buffer (10 mM, Life Technologies Ltd., Paisley, U.K.) 
and MTT (50 pi, 5 mg/ml in PBS) was added to all 96 wells. Plates were 
incubated in the dark at 37°C, in an atmosphere of 2% C 0 2 in air for 4 hours. 
The medium and MTT was removed and the formazan crystals dissolved by 
addition of 200 pi of dimethyl sulphoxide to each well followed by 25 pi of 
Sorensen’s glycine buffer (0.1 M glycine, 0.1 M NaCl adjusted to pH 10.5 with 
NaOH).
The absorbance was measured with a microplate reader (Bio-Rad Model 
3550, Bio-rad Laboratories Ltd., Hemel Hempstead, Hertfordshire, U.K.) at a 
wavelength of 570 nm. The first row of the plate that had contained medium and
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MTT but no cells was used as a blank for the plate reader. The absorbance 
values were plotted versus drug concentrations on semilog graph paper, and drug 
sensitivity was expressed as the ID50 defined as the drug concentration required 
to reduce the absorbance value to 50% of that of the control untreated cells.
Conditions were optimised such that cells underwent at least 2 population 
doublings during the period between removal of drug and the end of the 
experiment. In addition absorbance was shown to be linear with viable cell 
number in the range used for these experiments.
Cytotoxic drugs
Doxorubicin was obtained as a sterile powder (Farmitalia, St. Albans, 
U.K.). It was prepared as a stock solution in distilled water at 2 mg/ml and 
stored at -20°C in aliquots of 100 or 200 pi. Daunorubicin (Sigma Chemical 
Company, Poole, U.K.) was prepared as a stock solution at 2 mg/ml in PBS, filter 
sterilised (pore size 0.22 pm, Millex-GS, Millipore Ltd., Watford, Herts, U.K.) 
and stored at -20°C in aliquots for up to 2 months. The resistance modulators 
verapamil and quinidine sulphate (Sigma Chemical Company, Poole, U.K.) were 
dissolved in PBS and filter sterilised just before use. Bepridil (Sigma Chemical 
Company, Poole, U.K.) was made up as a stock solution just before use at a 
concentration 2 mM by addition of 200 pi of polyethylene glycol 200 (Merck, 
Thomlibank, Glasgow, U.K.) to 4.03 mg of bepridil followed by addition of 4.8
ml of PBS.
Estimation of cellular drug accumulation
Cellular drug accumulation was determined according to the method 
described by Plumb et al (1990). Cells were trypsinised, counted and plated out 
into 6-well plates (Nunclon, Life Technologies Ltd., Paisley, U.K.) at a density of 
106 cells per well in 5 ml of medium and grown at 37°C in a humidified 
atmosphere of 2% C 0 2 for 24 hours. The medium was removed and the cells 
were fed with 4.5 ml of fresh medium and allowed to equilibrate for 1 hour at 
37°C, 2% C 0 2.
Daunorubicin and 3H-daunorubicin (3.2 Ci/mmol, New England Nuclear, 
Stevenage, Herts, U.K.) was added as a 10 x concentrated stock (0.5 ml per well) 
to give a final concentration of 1 pM and 0.01 pCi/ml. In some experiments 
doxorubicin and 14C-doxorubicin (76.6 mCi/mmol, Amersham International, 
Amersham, Bucks, U.K.) was added to give the same final concentrations. When 
resistance modulators were used, cells were fed with 4 ml of medium and the 
modulator was added (0.5 ml/well) as a 10 x concentrated solution.
At specified times plates were placed on ice and the medium removed. 
Cells were washed twice with 5 ml of ice cold PBS and trypsin/EDTA 
(0.25%/lmM, 0.5 ml/well) was added. Plates were incubated at 37°C for 5 
minutes to remove cells and wells were washed twice with PBS (0.5 ml) and the
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cells plus washes transferred to scintillation vials. Scintillation fluid (10 ml, 
Ecoscint, National Diagnostics, B.S. & S. Ltd., Edinburgh, U.K.) was added to the 
vial and the contents mixed. Radioactivity was determined in a scintillation 
counter (Packard Liquid Scintillation Spectrometer, Model 3255, Canberra, 
Packard Ltd., Pangboume, Berks, U.K.). A sample (25 pi) of the concentrated 
drug stock was also counted in order to determine the specific activity of the drug. 
This value was used to convert cpm to pmoles of drug. Cell counts were 
determined in 3 additional wells and drug accumulation is expressed as 
pmoles/106 cells. In some cases accumulation is expressed as a concentration 
based on the estimated volume of the cell.
Estimation of drug efflux
Drug efflux was determined by the method described by Fojo et al (1985). 
Cells were plated into 6-well plates as for the drug accumulation assay. They 
were incubated for 1 hour at 37°C with daunorubicin and 3H-daunorubicin (1 pM, 
0.01 pCi/ml) in 5 ml of glucose free Hank’s Balanced Salt Solution containing 
0.075% sodium bicarbonate and sodium azide (10 mM, Sigma Chemical 
Company, Poole, U.K.). The azide was included in the glucose-free medium to 
fully inhibit energy dependent efflux during the drug loading period. Thus more 
or less equalising drug accumulation in the parent and resistant cells. In some 
experiments cells were incubated with drug in culture medium containing
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verapamil (6.6 or 50 pM). Medium and drug were then removed and the cells 
washed twice with ice cold PBS. The drug loaded cells were incubated in drug 
and azide-free culture medium at 37°C and at specified times the medium was 
removed, the cells washed with ice cold PBS and total intracellular daunorubicin 
determined as for the drug accumulation studies.
Statistical analysis
Where necessary the results were subject to non-paired Student t test using 
Minitab Data Analysis Software (Release 7.1-Standard version, Minitab, Inc., 
1989).
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Results
Effect of resistance modulators on the sensitivity to doxorubicin in a panel of 
human cell lines
Table I shows the sensitivities of a number of cell lines to doxorubicin 
either alone or when exposed to doxorubicin in the presence of one of 3 
resistance modulators. The two multidrug resistant cell lines where resistance was 
derived in vitro were highly resistant to doxorubicin with resistance factors (drug 
sensitivity of the resistant cell line divided by that of the sensitive parent cell line) 
of 10950 (ovarian line 2780AD) and 580 (breast line MCF7/Adr). The four non­
small cell lung cancer cell lines showed similar sensitivities to doxorubicin to the 
breast parent line MCF7 whereas the ovarian parent line A2780 was about 50 
fold more sensitive to doxorubicin. Verapamil (6.6 pM) sensitised 6 of the 8 cell 
lines to doxorubicin. For the MDR cell lines sensitivities were increased by 13 
(2780AD) and 15 (MCF7/Adr) fold whereas verapamil had no effect on the 
sensitivity of the parental cell lines (Fig. 1A). A much smaller but significant (2-3 
fold, P < 0.05 & P < 0.01) increase in sensitivity was observed for the 4 non­
small cell lung cancer cell lines. Both bepridil (6.6 pM) and quinidine (6.6 pM) 
sensitised the MDR cell lines to doxorubicin to a similar degree as observed with 
verapamil (6.6 pM). In contrast, bepridil and quinidine had no effect on the 
sensitivity of the 4 non-small cell lung cancer cell lines to doxorubicin (P > 0.20). 
In no experiment did this concentration of modulators alone significantly alter the
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growth or viability of the cell lines (Table II).
Effect of verapamil on the sensitivity of the MDR cell lines to daunorubicin
The sensitivity to daunorubicin of the two multidrug resistant cell lines and 
the respective parental cell lines is shown in Table III. Also shown is the effect 
of various concentrations of verapamil on the sensitivity of the cells to 
daunorubicin. Both multidrug resistant cell lines were cross resistant to 
daunorubicin with resistance factors of 860 (2780AD) and 370 (MCF7/Adr), 
comparable to those for doxorubicin (Table I). Verapamil (6.6 pM) sensitised 
both resistant cell lines to daunorubicin (Fig. IB) but the degree of sensitisation 
was greater for 2780AD (35 fold) and smaller for MCF7/Adr (11 fold) than that 
observed with doxorubicin. For 2780AD sensitisation with verapamil was dose 
dependent (Table III). Verapamil had no effect on the sensitivity of parent 
MCF7 or A2780 cells to daunorubicin.
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ID50 (nM)
Cell line DOX DOX+Vp DOX+ Bp DOX+Qn
A2780 0.95 + 0.34 
(1.0)
0.71 + 0.29 
(1.3)
1.32+0.38
(0.8)
0.59±_0.23
(1.6)
2780AD 10400+.1390
(1.0)
800+.46
(13.0*)
1320+60
(7.9*)
1500±220
(6.9*)
MCF7 78.0±13.0
(1.0)
72.0±10.0
(1.1)
ND ND
MCF7/Adr 44870±1070
(1.0)
2900+.215
(15.5**)
6700±700
(6.7**)
7000+.400
(6.4**)
A549 48.3±2.3
(1.0)
12.6±.1.7
(3.8**)
42.6±7.3
(1.1)
2>5.1±32
(1.4)
WIL 88.2±1.7
(1.0)
28.7 + 2.7 
(3.1**)
83.3±_6.9
(1.1)
76.5+_10.1
(1.2)
SK-MES 53.7 + 8.0 
(1.0)
18.0±2.4
(3.0*)
50.3±5.8
(1.1)
54.7+^.5
(1.0)
L-DAN 55.5 + 3.1 
(1.0)
22.7 +.1.3 
(2.4**)
60.2 + 7.8 
(0.9)
59.8±4.7
(0.9)
Table I Doxorubicin (DOX) sensitivities of a panel of cell lines determined in 
the presence and absence of resistance modulators by the MTT assay. Cells were 
exposed to the drug for 24 hours and the modulators, verapamil (Vp), quinidine 
(Qn) and bepridil (Bp) were all used at 6.6 pM. Values are the mean _+_ standard 
error of 3 independent determinations and the ID50 is defined as the drug 
concentration required to reduce the absorbance to 50% of that of the control, 
untreated wells. The ratio of the ID50 in the absence of modulator to that in the 
presence of modulator is shown in parentheses and the asterisks denote the 
significance of any difference (* P < 0.05, ** P < 0.01; ND, not done).
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Figure 1 Dose response curves for human ovarian multidrug resistant cell line 
2780AD and its drug sensitive counterpart A2780 to doxorubicin (A) and 
daunorubicin (B). Cells were exposed to drug for 24 hours in the presence and 
absence of verapamil (6.6 \ iM )  and sensitivity was determined by the MTT assay. 
For the estimation of cell survival absorbance values are expressed as a 
percentage of the absorbance of the control, untreated wells and values are the 
mean ± _  standard error of triplicates from one representative experiment.
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Absorbance (% of control)
Cell line Verapamil Bepridil Quinidine
A2780 102.0 +.9.8 98.8 Jl 2.5 101.1 +_ 1.5
2780AD 105.4 +_ 1.2 99.0 +_ 2.3 98.6 +_ 3.6
MCF7 101.7 +_ 2.6 102.3 ±.3.0 99.2 ±_ 1.7
MCF7/Adr 97.9 +_2.4 100.2 +_ 1.3 98.7 +.2.3
A549 95.4+.4.8 95.9 +.3.7 100.6 +. 1.9
WIL 99.5 +.2.1 97.9 +_ 3.5 98.4 +_ 1.7
SK-MES 101.9 +.5.1 99.6 +.2.2 96.2 +_3.6
L-DAN 99.0 +_4.9 90.2 +_ 5.3 93.9 ±_ 5.6
Table II Effect of the three resistance modulators on cell survival. Results are 
the mean absorbance (+. standard error) of the wells exposed to modulator alone, 
expressed as a percent of the absorbance of the control, untreated wells and are 
from the plates used in the MTT assays from Table I.
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Anthracycline accumulation in the presence and absence of verapamil
Figure 2 shows the total amount of anthracycline accumulated with time 
when cells (A2780 & 2780AD) were incubated with either doxorubicin or 
daunorubicin in the presence and absence of verapamil (6.6 pM). Drug 
accumulation increased with time for A2780 and had not reached a plateau after 
incubation for 5 hours. At all time points the amount of daunorubicin per cell 
was twice that of doxorubicin. Cell line 2780AD accumulated much less drug 
than A2780 and for both daunorubicin and doxorubicin accumulation was 
maximal after incubation for 1 hour. At this time the cells had accumulated 
about half as much doxorubicin and one sixth as much daunorubicin as the 
parental cell line. After 5 hours, A2780 had accumulated 4 times more 
doxorubicin and 16 times more daunorubicin than 2780AD.
Verapamil (6.6 pM) increased the amount of both doxorubicin and 
daunorubicin accumulation by 2780AD by about 2 fold. Accumulation in A2780 
was not affected by verapamil (Fig. 2). For doxorubicin in the presence of 
verapamil the points are identical to those for doxorubicin alone and these data 
are not shown for clarity. Thus in the presence of verapamil (6.6 pM) A2780 
accumulated 2 times more doxorubicin and 8 times more daunorubicin than 
2780AD after 5 hours.
Similar results were obtained with cell lines MCF7 and MCF7/Adr (Fig. 
3). After 5 hours MCF7 accumulated 14 times as much doxorubicin as did 
MCF7/Adr.
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Effect of energy deprivation and verapamil on daunorubicin accumulation
Figure 4 shows the total amount of daunorubicin accumulated by A2780 
and 2780AD when incubated for 1 hour in daunorubicin (1 pM). Cells were 
incubated with daunorubicin either in culture medium alone, in medium 
containing verapamil (6.6 pM) or in glucose-free Hank’s balanced salt solution 
containing sodium azide (10 mM). In regular culture medium, A2780 
accumulated about 11 times more daunorubicin than 2780AD. However when 
incubated in the absence of an energy supply there was no significant difference 
(P > 0.05) between the total amount of drug accumulation in the two cell lines 
and the levels were similar to the amount accumulated by A2780 in the presence 
of an energy supply. Addition of verapamil (6.6 pM) to the culture medium had 
no effect on daunorubicin accumulation in A2780. Verapamil (6.6 pM) doubled 
accumulation of daunorubicin in 2780AD.
Daunorubicin efflux
Figure 5 shows the amount of daunorubicin retained by cells when loaded 
with daunorubicin in glucose-free Hank’s balanced salt solution in the presence 
of sodium azide and then transferred to drug free culture medium. Very little of 
the accumulated drug was lost from the parental A2780 line. After 30 minutes 
82% of the drug was retained by the cells. In contrast; 83% of the accumulated
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drug was lost from the resistant 2780AD line in the first 5 minutes after transfer 
into drug free medium. The cells continued to lose drug at a slower rate such 
that after 30 minutes only 7 % of the initial accumulated drug remained.
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ID50 (nM)
Cell line DNR + Vp 
(1.65 pM)
+ Vp 
(3.3 pM)
+ Vp 
(6.6 pM)
A2780 4.6 + 0.1 
(1.0)
4.3±0.3
(1.1)
5.9+_1.6
(0.8)
4.8±0.2
(1.0)
2780AD 3970±260
(1.0)
496.0±105.7
(8.0**)
239.0±61.0
(16.6**)
112.0±5>.3
(35.4**)
MCF7 29.0±0.8
(1.0)
ND ND 24.0±_1.6
(1.2)
MCF7/Adr 10720±710
(1.0)
ND ND 940.0±76.0
(11.4**)
Table III Daunorubicin (DNR) sensitivities of P-glycoprotein-expressing 
multidrug resistant cell lines (2780AD & MCF7/Adr) and drug sensitive 
counterparts (A2780 & MCF7) in the presence and absence of verapamil 
determined by the MTT assay (see Table I legend). Values are the mean +_ 
standard error of 3 observations.
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Figure 2 Total cellular doxorubicin (A) and daunorubicin (B) accumulation by 
A2780 and 2780AD assessed using liquid scintillation counting. Cells were 
incubated for various times in drug (1 p.M, 0.01 pCi/ml) in the presence and 
absence of verapamil (6.6 tiM) at 37°C. Results are the mean of 3 observations 
and standard error bars are shown when larger than the symbols.
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its drug sensitive parent line MCF7. See Figure 2 legend for details.
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Figure 4 Effect of verapamil and energy deprivation on daunorubicin 
accumulation by cell lines A2780 and 2780AD following an 1 hour incubation with 
drug (1 pM. 0.01 pCi/mi) either in culture medium containing verapamil (6.6 pM) 
or in glucose-free Hank’s balanced salt solution containing sodium azide (10 miM). 
Total cellular drug (pmoles/106 cells) was measured using liquid scintillation 
counting and presented as percentages of control (A2780, incubated with 
daunorubicin only) for comparisons. Bars are the mean ± _  standard error of 3 
determinations.
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Figure 5 Daunorubicin efflux from ceil lines A2780 and 2780AD determinea 
by liquid scintillation counting. Cells were loaded with drug (1 pM. 0.01 pCi/ml) 
in glucose-free Hank’s balanced salt solution containing sodium azide (10 mM) 
for 1 hr at 37°C, washed ana transferred to culture medium. Cells were collected 
at specified times and radioactivity measured. Results are the mean +_standara 
error of triplicates from one representative of 2 observations showing similar 
results.
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Discussion
These results show clearly that verapamil can sensitise the two in vitro 
derived human multidrug resistant cell lines to both doxorubicin and 
daunorubicin. In both cell line sensitisation is associated with decreaseo drug 
accumulation and a rapid drug efflux mechanism. Quinidine and bepridil also 
sensitised both cell lines to doxorubicin but the degree of sensitisation was smaller 
than that seen with an equimolar concentration of verapamil. In contrast, 
verapamil but not quinidine or bepridil sensitised the four non-small cell lung 
cancer cell lines to doxorubicin.
Verapamil (6.6 pM) increased the doxorubicin sensitivity of the human 
ovarian multidrug resistant line 2780AD by 13 fold and that of the human breast 
multidrug resistant line MCF7/Adr by 15 fold. This confirms previous 
observations (Ford et al, 1991; Plumb et al, 1990; Rogan et al, 1984). The degree 
of sensitisation is small compared with the resistance factors of the cell lines. 
This discrepancy can be accounted for in part by the presence of other 
mechanisms of drug resistance within these cell lines such as altered 
topoisomerase II expression (Sinha et al, 1988) and changes in the activities of 
drug detoxification pathways (Batist et al, 1991; Hamilton et al, 1985; Ozols et al, 
1988). Both the 2780AD and MCF7/Adr were cross-resistant to daunorubicin 
and the resistance factors when compared to the drug sensitive parental cell lines 
were similar to those obtained for doxorubicin. The effect of verapamil (6.6 pM) 
on the daunorubicin sensitivity of 2780AD (35 fold) was greater than that
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observed with doxorubicin. In contrast, the effect on the daunorubicin sensitivity 
of MCF7/Adr (11 fold) was slightly smaller than the effect on doxorubicin 
sensitivity (Tables I & III). Previously, it has been shown that verapamil sensitises 
both multidrug resistant cell lines to doxorubicin in a dose-dependent manner 
(Plumb et al, 1990). This finding is consistent with the dose-dependent effect of 
verapamil in the daunorubicin sensitivity of cell line 2780AD (Table III).
In both 2780AD and MCF7/Adr, resistance to doxorubicin is associated 
with a marked reduction in overall drug accumulation (Figs. 2 & 3; Louie et al, 
1986; Schuurhuis et al, 1987). Sensitisation by verapamil (6.6 pM) is accompanied 
by a two fold increase in drug accumulation in the two cell lines. Whilst 
verapamil has no effect on the drug sensitivity of the parental cell lines A2780 
and MCF7, it does produce a small though not significant (P > 0.05) increase in 
doxorubicin accumulation in MCF7. This effect might be related to the high 
concentration of drug used for the accumulation studies. Whilst 1 pM 
doxorubicin is well below the ID50 concentration for cell line MCF7/Adr it is 
about 40 times the ID50 for cell line MCF7. This concentration of drug was 
however necessary in order to detect drug accumulation in the drug resistant cell 
lines.
Accumulation of doxorubicin and daunorubicin were compared in the 
ovarian cell lines. Cell line 2780AD also showed a marked reduction in 
daunorubicin accumulation (Fig. 2) consistent with the observation that it is cross 
resistant to this drug. However, cell line A2780 accumulated twice as much 
daunorubicin as doxorubicin. This may be related to the increased lipopholicity
44
of daunorubicin when compared with doxorubicin which facilitates entry into the 
cell (Arcamone, 1985; Gewirtz & Yanovich, 1987). The magnitude of the 
difference in drug accumulation between A2780 and 2780AD was much greater 
(16 fold) for daunorubicin than for doxorubicin (4 fold). It is therefore surprising 
that verapamil (6.6 pM) only doubled daunorubicin accumulation in 2780AD, the 
same factor as observed for doxorubicin, yet sensitisation was greater with 
daunorubicin than doxorubicin. This observation does, however, indicate that the 
potential effects of verapamil on drug sensitivity, distinct from the direct effects 
on P-glycoprotein, are more apparent with daunorubicin than with doxorubicin. 
If so then daunorubicin is more suitable drug for studies of the effects of 
verapamil on intracellular drug distribution.
Decreased drug accumulation in cell line 2780AD appears to be accounted 
for by an energy dependent drug efflux mechanism. Incubation of cells for 1 hour 
in drug in the presence of sodium azide and in the absence of an exogenous 
energy supply results in identical drug accumulation in cell lines A2780 and 
2780AD (Fig. 4). If the cells are then transferred to drug-free medium in the 
presence of an energy supply 93% of the accumulated drug is lost from cell line 
2780AD in the first 30 minutes. In contrast very little drug is lost from cell line 
A2780 in this same period (Fig. 5). Whether the entire efflux mechanism is due 
to the presence of P-glycoprotein is not clear. Verapamil was only able to inhibit 
a fraction of the drug efflux from cell line 2780AD at a concentration that has 
maximal effects on drug sensitivity (Plumb et al, 1990). However, it cannot be 
assumed that verapamil is capable of complete inhibition of the activity of P-
glycoprotein. Perhaps the use of a specific blocking antibody would be able to 
answer this question (Broxterman et al, 1988; Pearson et al, 1991; Rittmann- 
Grauer et al, 1990 & 1992).
The two other resistance modulators included in this study, quinidine and 
bepridil, were also able to sensitise both 2780AD and MCF7/Adr to doxorubicin. 
However, the modulation factors were smaller than those achieved with verapamil 
(Table I). Sehested et al (1989) have shown that even though quinidine was able 
to inhibit vincristine binding to plasma membrane vesicles from drug resistant 
cells more effectively than verapamil the effect of verapamil on drug sensitivity 
was greater than that of quinidine. Schuurhuis et al (1987) reported that bepridil 
was equally effective when compared with verapamil at 4 pM in sensitising cell 
line 2780AD to doxorubicin. However, they noted that at lower concentrations 
verapamil was more effective than bepridil and they did not compare the 
modulators at concentrations above 4 i^M. As with verapamil neither bepridil nor 
quinidine altered the sensitivity of the drug sensitive parental cell lines A2780 and 
MCF7.
Of the four non-small cell lung cancer cell lines studied only WIL shows 
significant expression of P-glycoprotein and this is only detectable at the level of 
mRNA. Significantly this cell line is the most resistant to doxorubicin of the 4 
non-small cell lung cancer cell lines and it is also more resistant than A2780 and 
MCF7. Surprisingly verapamil was able to sensitise, albeit modestly (2-3 fold), 
the doxorubicin sensitivity of all four non-small cell lung cancer cell lines (Table 
I). Sensitisation by verapamil was not greater for WIL than for the other cell
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lines. In contrast to the results for verapamil, bepridil and quinidine had no 
effect on the drug sensitivity of the four non-small cell lung cancer cell lines. 
Although sensitisation by verapamil in WIL can possibly be explained by effects 
on P-glycoprotein this is unlikely to explain modulation in the three cell lines with 
undetectable levels of P-glycoprotein (A549, SK-MES & L-DAN). Furthermore, 
if the effects on WIL are due to P-glycoprotein it is surprising that neither 
bepridil or quinidine had any effect on drug sensitivity. These observations are 
consistent with a previous report that has shown modulation of drug sensitivity by 
verapamil but not other modulators in P-glycoprotein negative cell lines (Cole et 
al, 1989). Furthermore, this supports suggestions that verapamil may have effects 
on intracellular drug distribution independent of effects on the drug efflux 
mechanism associated with P-glycoprotein (Bass et al, 1990; Coley et al, 1991; 
Hindenburg et al, 1989; Schuurhuis et al, 1991; Slapak et al, 1990).
In summary, verapamil is a potent modulator of drug sensitivity in cell lines 
that overexpress P-glycoprotein. The effects on drug sensitivity in both 
MCF7/Adr and 2780AD are of greater magnitude than the effects on drug 
accumulation. Furthermore, verapamil but not other resistance modulators can 
sensitise cell lines with low or negligible expression of P-glycoprotein. These 
observations clearly indicate the potential of verapamil as a resistance modulator 
of great mechanistic interest at least in vitro.
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CHAPTER 3
Effect of verapamil on intracellular drug distribution
Introduction
In the previous chapter two multidrug resistant cell lines, 2780AD and 
MCF7/Adr, were shown to accumulate less drug than their respective drug 
sensitive parent cell lines. Under normal growth conditions, the steady-state 
cellular drug content of the MDR cell lines was about 10% of that of their drug 
sensitive counterparts. These two drug resistant variants are known to express P- 
glycoprotein and the activity of this drug efflux pump probably accounts, at least 
in part, for the drug resistance. Consistent with this is the observation that 
verapamil (6.6 pM) increases the overall drug accumulation and drug sensitivity 
of the two cell lines. It was apparent, however, that whilst drug sensitivity was 
increased by 10-30 fold by verapamil (6.6 pM) drug accumulation was increased 
only by 2 fold (Chapter 2 Table III & Fig. 2). Furthermore, Gervasoni et al 
(1991) have shown that HL-60/AR cells are 100-200 fold resistant to 
daunorubicin but drug accumulation was only 50-71% of that in the parental cell 
line HL-60S from which they were derived. This cell line does not express P- 
glycoprotein. Although there is not necessarily a one to one relationship between
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these two parameters, the size of the discrepancy suggested that verapamil may 
have effects other than just via inhibition of P-glycoprotein. In addition verapamil 
was shown to sensitise cell lines that had little or no expression of P-glycoprotein 
(Chapter 2 and Cole et al, 1989; Coley et al, 1991a, Nygren et al, 1991).
Recently, several drug resistant cell lines that do not express P-glycoprotein 
have been shown to accumulate less drug than the cell line from which they were 
derived (Cole et al, 1989; Coley et al, 1991; Nygren et al, 1991). Decreased drug 
accumulation was found to precede increased expression of P-glycoprotein 
during induction of resistance in murine erythroleukaemia cells (Slapak 
et al, 1990). Furthermore, Bass et al (1990) showed that induction of drug 
resistance occurred prior to expression of P-glycoprotein in human lung cancer 
cells. Thus decreased drug accumulation and development of drug resistance is 
not always related to P-glycoprotein activity.
An increase in membrane traffic and enhanced exocytosis was observed in 
drug resistant P388 leukaemia cells and Ehrlich ascites tumour cell lines and this 
was associated with enhanced drug extrusion from the cells (Sehested et al, 1987a, 
b). Moreover, vinblastine resistant human lymphoblastic leukaemic CEM cells 
had lower levels of lysosomal enzymes, such as N-acetylglucosaminidase and p- 
galactosidase, and a greater rate of secretion of these enzymes than did the drug 
sensitive CEM cells (Warren et al, 1991). Whether the exocytosis is linked to the 
expression of P-glycoprotein in these cells is not known but any drug present 
within the lysosomes would be more rapidly removed from the cell. A number 
of cytotoxic drugs have been shown to distribute into subcellular vesicles and
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organelles (Gervasoni et al, 1991; Hindenburg et al, 1989). This may represent 
an alternative mechanism for drug resistant cell lines that exhibit a drug 
accumulation deficiency but not necessarily associated with P-glycoprotein 
expression (Beck, 1987). It is interesting to note that verapamil can inhibit 
degradation of low density lipoproteins in HeLa cells. The low density 
lipoproteins are degraded in the lysosomes and verapamil was shown to decrease 
the activity of a number of lysosomal enzymes including cathepsin B, (J- 
hexosaminidase and acid phosphatase (Akiyama et al, 1985).
The aim of the experiments described in this chapter was to determine 
whether multidrug resistant cell lines demonstrate altered intracellular drug 
distribution and if so whether verapamil alters the distribution. There are several 
methods available that could be used to study drug distribution. The simplest 
technique for drugs such as the anthracyclines which are inherently fluorescent is 
to observe live cells with the fluorescence microscope. This technique has the 
advantage of speed since no preparation of the cells is required before 
observation and with the added discriminatory powers of a laser-scanning confocal 
microscope can give detailed information on the location of fluorescence 
(Gervasoni et al, 1991). A major disadvantage of the method is that of 
fluorescence quenching, particularly of drug bound to DNA or other cellular 
components. The use of a radioactively labelled drug in association with 
autoradiography can overcome the problem of fluorescence quenching but the 
technique is obviously much more time consuming. Subcellular fractionation has 
been used to determine the drug content of cellular organelles (Londos-Gagliardi
et al, 1980). However, the processing time involved is of the order of hours and 
it is quite possible that much of the unbound drug will be lost during preparation 
of the fractions.
Initial studies were carried out by fluorescence but in the absence of the 
precision of the confocal microscope only limited information was obtained. The 
technique of autoradiography was therefore developed for detailed studies of 
intracellular drug distribution. Although the two pairs of MDR cell lines (A2780 
: 2780AD and MCF7 : MCF7/Adr) were both selected with doxorubicin the 
experiments were performed with the closely related anthracycline daunorubicin 
(Fig. 1). These studies required the low energy p particles and hence the short 
path length of tritium in order that the grains appear as close as possible to the 
site of origin of the radioactivity. Doxorubicin is only available with a carbon 14 
label and the energy and hence path length of p particles from this radionuclide 
is too long for grains to remain associated with the site of origin of the 
radioactivity (Aherne et al, 1977).
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Figure 1 The structures of the anthracvclines, daunorubicin and doxorubicin. 
There is a difference of oniv a hydroxyl group between these two drugs at the C- 
14 site on the C-9 side chain.
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Materials and Methods
Cell lines
Two P-glycoprotein-expressing MDR cell lines, 2780AD and MCF7/Adr, 
and the respective wild type parental cell lines, A2780 and MCF7, were used in 
these studies. The growth conditions for these cell lines have been presented in 
Chapter 2.
Cellular fluorescence
Cells (3 x 104) were seeded into 35-mm plastic tissue culture petri dishes 
(Nunclon, Life Technologies Ltd., Paisley, U.K.) in 3 ml of medium and were 
grown at 37°C for 3 days. The medium was then replaced with 3 ml of fresh 
medium and cells were incubated for 1 hr to allow equilibration of pH and 
temperature. Daunorubicin was then added to give a final concentration of 2 pM 
or 10 pM. In some dishes verapamil was added at the same time to give a final 
concentration 6.6 pM.
At various times dishes were placed on ice, the drug and medium removed 
and the cells washed twice with ice cold PBS. Cells were mounted in PBS with 
a glass coverslip and viewed immediately under oil immersion with a fluorescence 
microscope (Polyvar, Leica UK Ltd., Milton Keynesr U.K.) fitted with a blue (475-
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495 nm) filter.
Autoradiography
Glass coverslips were cleaned and sterilised before use as summarised
below.
95% Ethanol 5 min
1 N Hydrochloride acid 5 min
Deionised distilled water 5 min
Deionised distilled water 4 x rinses
95% Ethanol 2 x
100% Ethanol 2 x
Oven 160°C 2 hr
Exponentially growing cells werqdisaggregatedwith trypsin and plated onto 
sterile glass coverslips in 6-well plates at a density of 2.5 x 104 cells/well (MCF7 
& MCF7/Adr) or 7.5 x 104 cells/well (A2780 & 2780AD) in 5 ml of medium. 
The cells were allowed to settle and grow at 37°C for 3 days.
The cells were fed with 5 ml of fresh medium and allowed to equilibrate 
for 1 hr. Daunorubicin and 3H-daunorubicin were added to give a final 
concentration of 1.0 pM and 0.1 pCi/ml. In some wells verapamil (3.3 or 6.6 pM 
final concentration) was added with the daunorubicin.
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At specified times, plates were placed on ice, the medium and drug 
removed and the cells washed three times with ice-cold PBS. The cells were then 
fixed for 5 min at 0-4°C in 1% paraformaldehyde (w/v in PBS, pH 7.0). The 
coverslips rinsed in PBS and left to dry at room temperature. Coverslips were 
mounted with the cells on the top surface onto clean microscope slides in DPX 
mountant (BDH, poole, U.K.) and allowed to air dry overnight.
Slides were coated with Kodak K-2 emulsion (Kodak Ltd., T.M. Kodak, 
Herts, U.K.) in the darkroom with a red safelight when necessary.
An appropriate amount of the emulsion was placed into a clean glass 
beaker and melted in a waterbath at about 40°C for 30 minutes with occasional 
gentle stirring with a clean glass rod. The melted emulsion was diluted with an 
equal volume of prewarmed deionised distilled water and transferred into a 
dipping vessel (Lab-Tek Cyto-Mailer, Life Technologies Ltd., Paisley, U.K.).
Slides were dipped one by one into the emulsion for about two seconds, 
removed slowly, excess emulsion allowed to drain off and then placed on a flat 
surface to dry. The dried slides were arranged into slide holders and kept in 
light-tight boxes with a pack of desiccant. The boxes were sealed with vinyl tape 
and stored at 4°C for six days.
Slides were then developed in the dark as follows:
Developer (Kodak D19, Kodak Ltd., Herts, U.K.) 2.5 min
Deionised distilled water 10 sec
Fixative (Ilford fixer, Ilford Ltd., Essex, U.K.) 7 min
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Deionised distilled water 10 sec
Hypocleaning agent (Kodak unifix, Kodak Ltd., Herts, U.K.) 1 min
Running tap water 20 min
Deionised distilled water 1 min
Air dry 2 days
Cells were stained with undiluted Giemsa (BDH, Poole, U.K.) for 1 min, 
and with diluted Giemsa (1 part Giemsa, 2 parts PBS) for 2 min followed by a 
two minute destain in PBS and a brief rinse with tap water.
Examination was carried out under oil immersion with a 100 x objective 
lens. Grain counts were performed with respect to the whole cell, the cytoplasm 
only and the nucleus only. In each case 20 cells per slide were assessed. 
Background counts were obtained by counting the grains in cell free areas similar 
in size to the cells. In all cases, the background count was less than 10% of the 
counts in the cells, and this was subtracted from the total grain counts.
Statistical analysis
All the data from autoradiography were analysed statistically using analysis 
of variance with Minitab Data Analysis Software (Release 7.1-Standard version, 
Minitab, Inc., 1989).
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Results
Intracellular localisation of daunorubicin fluorescence in the ovarian cancer cell 
lines
Plate 1 shows the distribution of daunorubicin fluorescence in the sensitive 
parental cell line A2780 (Plate 1A & IB) and in the drug resistant cell line 
2780AD (Plate 2A & 2B)? Cells were incubated with daunorubicin (DNR, 10 
|iM) for 1 hour. For A2780 cells there is an abundance of DNR fluorescence in 
both the nucleus and cytoplasm and the fluorescence in the cytoplasm is punctate. 
In contrast, very little fluorescence is apparent in the cytoplasm of cells from 
2780AD and almost none is visible in the nucleus (Plate 2A). However, when 
cells were incubated with DNR in the presence of verapamil (6.6 pM) bright 
fluorescence was apparent throughout both the nucleus and cytoplasm of cells 
from the resistant line, 2780AD (Plate 2B). Furthermore, fluorescence was also 
clearly associated with the chromatin and the nuclear membrane.
Verapamil had no effect on the fluorescence intensity or distribution in 
A2780. Similar results were obtained when cells were incubated with DNR (2 
pM) although the intensity of the fluorescence was much less in both cell lines 
(results not shown).
a For photography cells were selected and focused under phase contrast.
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Plate 1 Daunorubicin fluorescence distribution in A2780. Cells grown in 35 
mm petri dishes for 3 days were incubated with daunorubicin (10 n.M) in the 
presence (B) and absence (A) of verapamil (6.6 p.M) for 30 minutes, washed and 
viewed under oil immersion with a fluorescence microscope fitted with a blue 
(475-495 nm) filter. Photomicrographs were taken with Kodak P800/1600 film 
with an objective magnification of 100 x.
Plate 2 Daunorubicin fluorescence distribution in 2780AD (see Plate 1 legend 
for details). (A) in the absence of verapamil (B) in the presence of verapamil.
Accumulation of 3H-daunorubicin in the ovarian cancer cell lines
Both A2780 and 2780AD showed a marked morphological heterogeneity. 
Two major cell types were apparent in these cell lines. The lightly stained large 
cells have a distinct nucleus and cytoplasm whereas the small heavily stained cells 
have no distinguishable cytoplasm (Plate 3A, 3B & 3C). 3H-daunorubicin 
accumulation was determined by autoradiography over an 8 hour time course. 
For A2780 both cell types showed a similar pattern of daunorubicin accumulation 
with a rapid increase in grain count up to 60 minutes after which no further 
increase was observed (Fig. 2). The large cells contained about 3 times as many 
grains as the small cells at all time points studied.
In contrast, very few grains were apparent in either cell type throughout 
the 8 hour time course for cell line 2780AD (Fig. 3). The zero time point was 
obtained by addition of 3H-daunorubicin followed by rapid removal and washing 
the cells. In these few seconds daunorubicin accumulation appears to have 
reached a maximum.
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Plate 3 Distribution of grains in cell lines A2780 and 2780AD. Cells grown on 
glass coverslips for 3 days were incubated with daunorubicin (1 pM, 0.1 pCi/ml) 
for 30 minutes, washed and fixed in paraformaldehyde (1%). The slides were 
coated with Kodak K-2 emulsion, exposed, developed and stained with Giemsa. 
Photomicrographs were taken with an objective magnification of 100 x 
(A) A2780 (B) 2780AD (C) 2780AD incubated with daunorubicin in the
presence of verapamil (6.6 pM).
Por photography cells were selected and focused under phase contrast.
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Figure 2 Total grain counts in small (A) and large (B) ceils of the parental ceil 
line A2780 following incubation of the cells with drug in the presence or absence 
of verapamil for specified times. Bars are the mean plus standard error of grain 
counts of 20 cells and results are from one representative of 4 similar 
observations. Background was less than 10% of the grain count and this was 
deducted from the total grain counts.
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Figure 3 Total grain counts in smail (A) and large (B) ceils of the resistant cell 
line 2780AD. See legend for Figure 2 for details. .Asterisks represent statistically 
significant difference (Two-tailed Student’s t test, * P  < 0.01; ** P  < 0.001) in 
grain count between cells incubated in the presence and absence of verapamil.
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Effect of verapamil on 3H-daunorubicin accumulation
Verapamil had no effect on DNR accumulation in cell line A2780 (Fig. 2). 
In contrast, a marked increase in grain counts was observed at all time points 
when 2780AD was incubated with DNR in the presence of verapamil (3.3 or 6.6 
pM). Up to 10 minutes the increase was independent of the concentration of 
verapamil. However, by 30 minutes the increase was greater for the higher 
concentration of verapamil (Fig. 3). In both the small and large cells 
accumulation was maximal at 30 minutes and decreased with longer exposures.
Distribution of grains between the nucleus and cytoplasm
Differential grain counts in the nucleus and cytoplasm were carried out on 
the large cells of both A2780 and 2780AD. For both cell lines over 80% of the 
DNR was present in the nucleus at all time points (Figs. 4 & 5; Table I). 
Verapamil had no significant effect (P > 0.05) on DNR distribution in A2780. 
For cell line 2780AD verapamil increased the grain count in both compartments 
but the increase was greater in the nucleus than in the cytoplasm (Fig. 5). Thus, 
the nucleus to cytoplasm ratio increased significantly (.P < 0.01) in the presence 
of verapamil (6.6 pM) (Table II).
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Figure 4 Grain counts in cytoplasm (A) and nucleus (B) of the large cells of 
A2780. See Figure 2 legend for details.
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Figure 5 Grain counts in cytoplasm (A) and nucleus (B) of the large ceils of 
2780AD. See legend for Figure 3 for details.
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Grain count (% of total)
- Verapamil + Vp (3.3 pM) + Vp (6.6 pM)
Time
(min)
Nucleus
Cytoplasm
N/C
Nucleus
Cytoplasm
N/C
Nucleus
Cytoplasm
N /C
92.1 92.2 91.2
10 11.7 11.8 10.4
7.9 7.8 8.8
92.9 93.5 90.5
30 13.1 14.4 9.5
7.1 6.5 9.5
90.3 91.6 89.5
60 9.3 10.9 8.5
9.7 8.4 10.5
88.0 91.0 90.3
120 7.3 10.5 9.3
12.0 9.0 9.7
86.4 89.9 86.3
240 6.4 8.9 6.3
13.6 10.1 13.7
83.7 84.3 88.0
480 5.1 5.4 7.3
16.3 15.7 12.0
Table I Percentage of total intracellular grain count in the nucleus and
cytoplasm and the ratio of nuclear to cytoplasmic (N/C) grain counts. Results are 
shown for large cells examined following incubation of the parental line A2780 
with daunorubicin (1.0 pM) and 3H-daunorubicin (0.1 pCi/ml) in the presence or 
absence of verapamil (3.3 or 6.6 pM) for the period of time specified. Values are 
mean of 20 cells and are representative of 4 independent observations showing 
similar results.
N /C  = Grain count in nucleus /  Grain count in cytoplasm
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Grain count (% of total)
- Verapamil + Vp (3.3 pM) + Vp (6.6 pM)
Time Nucleus Nucleus Nucleus
N/C N/C N /C
(min) Cytoplasm Cytoplasm Cytoplasm
90.5 93.2 92.1
10 9.5 13.7 11.7
9.5 6.8 7.9
84.8 92.2 92.6
30 5.6 11.8 12.5
15.2 7.8 7.4
82.0 93.0 91.6
60 4.6 13.3 10.9
18.0 7.0 8.4
84.0 85.6 89.8
120 5.3 5.9 8.8
16.0 14.4 10.2
82.4 88.8 88.6
240 4.7 7.9 7.8
17.6 11.2 11.4
68.8 89.0 90.3
480 2.2 8.1 9.3
31.2 11.0 9.7
Table II Percentage of total intracellular grain count in the nucleus and 
cytoplasm and the ratio of nuclear to cytoplasmic (N/C) grain count for the 
resistant line 2780AD. See Table I legend for details. The ratio of N /C grain 
count are significantly higher in cells incubated with verapamil (6.6 pM) than 
those in cells incubated in the absence of verapamil (P < 0.01, analysis of 
variance). Values are mean of 20 large cells for individual groups and are 
representative of 4 independent observations showing similar results.
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Accumulation of 3H-daunorubicin in the breast cancer cell lines
3H-daunorubicin accumulation was studied over a 5 hour period for the 
parental breast cancer cell line MCF7 and its resistant counterpart MCF7/Adr. 
For MCF7 grain counts showed a gradual increase throughout the time course 
(Fig. 6B). In contrast, grain counts in cell line MCF7/Adr reached a maximum 
after 1 hour and the total counts per cell were about 8% of that for cell line 
MCF7 (Fig. 6A). As for the ovarian cell lines the majority of the grains were 
present in the nucleus of the cells (Plate 4A, 4B & 4C; Figs. 7 & 8 and Tables III 
& IV). However, for MCF7/Adr the nuclear grain count was only about twice 
that in the cytoplasm such that the nuclear to cytoplasmic ratio was much smaller 
than that for the parental cell line MCF7 (Tables III & IV).
Effect of verapamil on 3H-daunorubicin accumulation in the breast cancer cell 
lines
Verapamil had no effect on 3H-daunorubicin accumulation in MCF7 except 
after incubation for 3 and 5 hours when the grain count was significantly (P < 
0.01) increased in the cytoplasm in the presence of verapamil (Fig. 7). For cell 
line MCF7/Adr the grain count in both the cytoplasm and nucleus was increased 
in the presence of verapamil (6.6 pM) and the increase was greatest in the 
nucleus (Fig. 8; Plate 4C). Thus in the presence of verapamil the nuclear to
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Plate 4 Distribution of grains in ceil lines MCF7 and MCF7/Adr. Cells were 
incubated as described in the Legend for Plate 3. (A) MCF7 (B) MCF7/Adr 
(C) MCl-7/Adr incubated with daunorubicin in the presence of verapamil (6.6 
pM )• p or photography cells were selected and focused under phase contrast.
cytoplasmic ratio of grain counts in MCF/Adr approached that of the parental 
cell line MCF7 (Tables III & IV).
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Figure 6 Total grain counts in the resistant line MCF7/Adr (A) and the 
parental line MCF7 (B) following incubation of the cells with drug in the
presence or absence of verapamil for specified times. Bars are mean plus 
standard error of 20 cells examined and results are from one of 2 similar
observations. See Figure 3 legend for statistics.
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Figure 7 Grain counts in cytoplasm (A) and nucleus (B) of the MCF7 cells. 
See Figure 6 legend for details.
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Figure 8 Grain counts in cytoplasm (A) and nucleus (B) of the MCF7/Adr 
cells. See legend for Figure 6 for details.
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Grain count (% of total)
- Verapamil + Verapamil (6.6 pM)
Time Nucleus Nucleus
N/C N/C
(min) Cytoplasm Cytoplasm
86.6 88.0
10 6.5 7.3
13.4 12.0
89.7 90.4
30 8.7 9.4
10.3 9.6
91.6 92.7
60 10.9 12.7
8.4 7.3
92.2 88.4
180 11.8 7.6
7.8 11.6
92.1 89.0
300 11.7 8.1
7.9 11.0
Table III Percentage of total intracellular grain count in the nucleus and 
cytoplasm and the ratio of nuclear to cytoplasm (N/C) grain count for the 
parental line MCF7. See Table I legend for details. Values are mean of 20 cells 
for individual groups and are representative of 2 independent observations 
showing similar results.
Grain count in nucleus
N/C ratio = _____________________ :_
Grain count in cytoplasm
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Grain count (% of total)
- Verapamil + Verapamil (6.6 pM)
Time Nucleus Nucleus
N/C N/C
(min) Cytoplasm Cytoplasm
77.1 92.4
10 3.4 12.2
22.9 7.6
70.7 88.7
30 2.4 7.8
29.3 11.3
65.7 85.9
60 1.9 6.1
34.3 14.1
60.9 84.6
180 1.6 5.5
39.1 15.4
66.7 83.3
300 2.0 5.0
33.3 16.7
Table IV Percentage of total intracellular grain count in the nucleus and 
cytoplasm and the ratio of nuclear to cytoplasmic (N/C) grain count for the 
resistant line MCF7/Adr. See Table I legend for details. Values are mean of 20 
cells and are representative of 2 independent observations showing similar results. 
The ratio of N/C grain count in the presence of verapamil was significantly larger 
than in the absence of verapamil (P < 0.01, analysis of variance).
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Discussion
Decreased drug accumulation in the ovarian cancer cell line 2780AD was 
clearly demonstrated both by daunorubicin autofluorescence and by 
autoradiography. By autoradiography it was possible to quantify the difference. 
Most of the drug was present in the nucleus of both sensitive and resistant cell 
lines but the ratio of the grain counts in the nucleus and cytoplasm was smaller 
in both resistant cell lines (2780AI^/[CF7/Adr). Verapamil increased the grain 
count in both nucleus and cytoplasm of the resistant cells but the increase was 
greatest in the nucleus such that the nucleus to cytoplasm grain count ratio 
approached that of the drug sensitive parental cell lines. Furthermore, the 
magnitude of the effects of verapamil on the grain count in the nucleus closely 
resembled that of the effects of verapamil on drug sensitivity.
Daunorubicin autofluorescence was used successfully to demonstrate 
decreased drug accumulation in cell line 2780AD. Whilst bright fluorescence was 
apparent throughout both the nucleus and cytoplasm of A2780 the fluorescence 
in 2780AD was close to the limit of detection by this technique (Plates 1 & 2). 
In the sensitive cell line, A2780, daunorubicin is associated with the chromatin 
and nuclear envelope. There are also defined areas of fluorescence in the 
cytoplasm suggesting that the drug may be associated with a subcellular 
compartment. This pattern of distribution is also seen in the drug resistant cell 
line 2780AD when the cells are incubated with daunorubicin in the presence of 
verapamil (6.6 pM, Plate 2B). However, based on cellular fluorescence verapamil
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appears to restore drug accumulation in 2780AD to the same level as observed
in A2780. It has already been demonstrated by the use of scintillation counting
that even in the presence of verapamil accumulation in 2780AD is only about
20% of that observed in A2780 (Chapter 2 Fig. 2). These results differ from the
fluorescence distribution of daunorubicin in A2780 reported by Broxterman et al
(1987). They observed that all fluorescence was nuclear when cells were
incubated with daunorubicin (2 pM) but do not state for how long. Although the
fluorescence distribution shown in Plate 1 was obtained with a daunorubicin
concentration of 10 pM a similar distribution was seen at a concentration of 2 pM
(results not shown). Since they do not illustrate their fluorescence study it is
difficult to compare results and the difference is possibly indicative of the 
of
subjective nature^ this technique in the absence of a method to quantify 
fluorescence. A further problem encountered with this technique is that of 
fluorescence quenching that arises when the drug binds to DNA or protein 
(Chaires et al, 1982; Rhodes et al, 1992; Schuurhuis et al, 1991). Thus the amount 
of drug in the nucleus, the proposed site of action of daunorubicin, is 
underestimated.
A punctate pattern of daunorubicin fluorescence in the cytoplasm of both 
sensitive and resistant cell lines has been reported previously (Gervasoni et al, 
1991). They hypothesised that daunorubicin distributes to the prelysosomal 
sorting compartment which is localised in the perinuclear region. This 
compartment is the site for plasma membrane and receptor recycling and sorting 
of vesicles to lysosomes or plasma membrane (Kornfeld, 1987). Localisation to
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such a compartment is consistent with a mechanism of drug removal via lysosomal 
trafficking.
The distribution of 3H-daunorubicin observed by autoradiography differed 
from that seen by autofluorescence of the drug. For both A2780 and 2780AD the 
majority of grains were located in the nucleus (Plate 2). Analysis of the grain 
counts was complicated by the presence of two cell types in roughly equal 
proportions in the two cell lines. The small cells with indistinguishable cytoplasm 
contained about a third as many grains as the large cells with clearly defined 
nucleus and cytoplasm (Figs. 2 & 3; Plate 3). For the small cells it was only 
possible to count total grains per cell whilst for the large cells differential grain 
counts between nucleus and cytoplasm were performed. After accumulation for 
1 hour total grain counts were about 30 fold lower in 2780AD than in A2780 (Fig. 
2) and about 90% of the grains were present in the nucleus of A2780 compared 
with 82% in 2780AD (Tables I & II). When cells were incubated with 
daunorubicin in the presence of verapamil the total grain count per cell was 
unchanged in A2780 but was increased by about 8 fold in 2780AD (Fig. 3). 
Furthermore, the proportion of the drug present in the nucleus in 2780AD 
increased to 92% in the presence of verapamil, comparable to that seen in A2780 
(Table II). Thus autoradiography has a major advantage over fluorescence drug 
distribution in that it allows quantification of the drug distribution. However, 
Willingham et al (1986) were able to quantify their fluorescence distribution and 
also reported that about 90% of the drug was present in the nucleus of drug 
sensitive KB3-1 cells. A similar proportion was found in the nucleus by cell
fractionation (Londos-Gagliardi et al, 1980).
Clearly, verapamil not only increased the total amount of drug taken up 
by the resistant line but also caused a redistribution of drug between nucleus and 
cytoplasm such that the proportion present in nucleus increased whilst that in the 
cytoplasm decreased. This effect was more marked in the multidrug resistant 
breast cell line MCF7/Adr. Total grain counts in MCF7/Adr were about 18 fold 
lower than those in MCF7 even after incubation with daunorubicin for 5 hours. 
Again about 90% of the grains were present in the nucleus of MCF7 cells but 
only about 70% of the grains were present in the nucleus of MCF7/Adr cells. 
Addition of verapamil (6.6 pM) during incubation of the cells with daunorubicin 
increased the total grain count in MCF7/Adr by about 5 fold and increased the 
proportion of drug present in the nucleus to about 85-90%. Verapamil caused a 
significant increase in daunorubicin accumulation in MCF7 after incubation for 
3 hours. Since verapamil had no effect on the drug sensitivity of this cell line this 
increase may be an artifact caused by the high concentration of daunorubicin used 
(1 pM) relative to the ID50 of this cell line (0.029 pM, Chapter 2 Table III). For 
both drug resistant cell lines the increase in the grain count in the nucleus caused 
by verapamil is closer to the degree of sensitisation observed. Verapamil (6.6 
pM) increased the sensitivity of 2780AD by 35 fold (Chapter 2 Table III) and 
MCF7/Adr by 11 fold (Chapter 2 Table III). By autoradiography verapamil 
increased the total grain count per cell by 8 fold and 5 fold and the nuclear grain 
count by 11 fold and 7 fold for 2780AD and MCF7/Adr, respectively. In contrast 
total drug accumulation determined by scintillation counting was increased by only
2 fold in both cell lines.
The discrepancy between these two techniques is probably due to loss of 
unbound drug during fixation and processing for autoradiography. Although the 
fixative used, paraformaldehyde, was chosen since it caused least loss of drug from 
the cells it has been reported that the majority of the cytoplasmic fluorescence is 
lost when cells loaded with daunorubicin are fixed in formaldehyde (Willingham 
et al, 1986). Thus the results obtained by autoradiography, particularly in terms 
of the ratio of grain counts between the nucleus and cytoplasm should be 
interpreted with caution. However, since the magnitude of the changes induced 
by verapamil agreeswith the magnitude of the effects on drug sensitivity and, since 
the nucleus is a prime target for the cytotoxic activity of daunorubicin it could be 
argued that bound drug represents active drug in terms of cytotoxicity (Ganapathi 
et al, 1984; Gigli et al, 1989; Noel et al, 1978; Terasaki et al, 1984).
The ability of verapamil to cause a redistribution of drug on multidrug 
resistant cells has been observed previously (Keizer et al, 1989; Schuurhuis et al, 
1989 & 1991). However, Schuurhuis et al (1991) reported that the nuclear to 
cytoplasm drug ratio, as measured by quantitative fluorescence, was reduced in 
a number of multidrug resistant cell lines but only in those that express P- 
glycoprotein could verapamil partially restore the ratio. These observations 
suggest that intracellular redistribution is a mechanism of drug resistance. It is 
not clear how this redistribution occurs although it has been hypothesised that a 
pump other than P-glycoprotein exists in intracellular vesicles (Schuurhuis et al, 
1991). Even in P-glycoprotein positive cell lines the protein has been widely
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reported to be present in the cell membrane but only one report suggests it is 
present in an intracellular membrane, the Golgi stack (Willingham et al, 1987). 
The multidrug resistant cell line HL-60/AR does not express P-glycoprotein but 
has been shown to accumulate less drug than the parent HL-60S cells when 
incubated in the same concentration of daunorubicin (Hindenburg et al, 1989). 
Fluorescence was shown to localise in the Golgi apparatus initially but then to 
relocate to the lysosomes and the mitochondria. When cells were incubated with 
drug in the presence of sodium azide and deoxyglucose the drug remained in the 
Golgi apparatus, suggesting that relocation is an energy dependent process. A 
number of reports have suggested that the membrane composition of drug 
resistant cells differs from that of the parental cell line from which they were 
derived (Cornwell et al, 1986a; Gervasoni et al, 1991; Mann et al, 1988; Perterson 
et al, 1983; Ramu et al, 1983a). Since anthracyclines such as daunorubicin have 
a high affinity for the membranes (Gottesman & Pastan, 1990; Raviv et al, 1990), 
these differences may account for changes in the rate of clearance of drug via 
pathways responsible for membrane recycling (Pagano & Sleight, 1985).
Thus there is evidence both from the present study and from the literature, 
that drug resistance can result not only from reduced drug accumulation but also 
from redistribution of drug within the cell. The results of this study indicate that 
verapamil not only increases the overall amount of drug accumulated but also 
enhances the proportion of the drug associated with the nucleus. There have 
been a number of attempts to synthesise novel anthracyclines that are not 
substrates for P-glycoprotein (Mross, 1991). Clearly, any change in the structure
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of the anthracycline will have the potential to alter the lipophilicity of the drug 
and hence influence the distribution pattern of the drug within the cell. Thus a 
compound which is a poor substrate for the efflux pump may not necessarily 
locate preferentially to the nucleus once in the cell (Rhodes et al, 1992). In this 
situation both total drug accumulation measurements and fluorescent drug 
distribution studies are of value. Whilst autoradiography can give valuable 
information with regard to the nuclear accumulation of the drug it is not suited 
to studies of cytoplasmic drug distribution due to loss of drug during fixation.
Finally, an interesting observation that arose from the autoradiography 
study was the morphological heterogeneity present in the ovarian cell lines. Two 
distinct populations that accumulated different amounts of drug were clearly 
apparent. Whilst some of the difference could be accounted for by differences 
in cell size the difference was largely associated with the nucleus. This 
observation suggested that populations with differing phenotypes in terms of drug 
sensitivity were present and this possibility is addressed in the next chapter.
Part of this work was presented at the British Association for Cancer 
Research meeting in Brighton in March 1990 (Luo et al, 1990).
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CHAPTER 4
Heterogeneity in the stability of the MDR phenotype between 
subpopulations of the ovarian cell line 2780AD
Introduction
During the analysis of drug accumulation by autoradiography described in 
the previous chapter (Chapter 3) a marked morphological heterogeneity was 
observed in the ovarian cell lines A2780 and 2780AD. A clear distinction could 
be made between densely stained cells with little cytoplasm and lighter staining 
cells with substantial cytoplasm. However, marked heterogeneity was apparent 
even within these two subgroups. Interestingly the heterogeneity was also 
apparent in cellular drug accumulation. Since most of the drug detected by 
autoradiography (about 90%) was associated with the nucleus the differences in 
drug accumulation between cells of different morphologies did not appear to be 
due simply to differences in cell size. These observations suggested that there are 
subpopulations within the two cell lines that differ in their handling of cytotoxic 
drugs.
Cell lines with the multidrug resistance phenotype are usually obtained by 
chronic exposure of cells to agents, such as doxorubicin, vincristine and colchicine,
80
over a prolonged period of time (Beck, 1983; Ling & Thompson, 1974;
Twentyman et al, 1986b). It is generally accepted that a single step selection does
not give rise to P-glycoprotein positive variants. The time required indicates that
some cells can adapt to the presence of the drug rather than resistance arising
from selection of a preexisting stable population within the parental cell line.
Adaptation probably involves genetic changes that are unstable (Courtenay &
Robins, 1972). This is supported by the fact that most P-glycoprotein positive
multidrug resistant cell lines need to be maintained in the presence of the
selecting agent in order to retain their resistance phenotype (Biedler et al, 1983;
Yang & Trujillo, 1990; Yusa & Tsuruo, 1989). Selection of a stable preexisting
population should result in a stable resistant population even in the absence of
the selecting agent. It is clear that a given cell line can give rise to a number of
resistant variants. In some cases this can be explained by different selection
protocols (Yang & Trujillo, 1990). However, in some cases similar protocols can
give rise to very different drug resistant sublines. For example, Twentyman et al
(1986b) developed a number of P-glycoprotein positive MDR cell lines from the
small cell lung cancer cell line NCI-H69 by chronic exposure to doxorubicin. In
contrast, Mirski et al (1987) used a similar selection procedure to derive a P-
glycoprotein negative MDR cell line from NCI-H69. Observations such as these 
are
suggest that there a number of mechanisms by which drug resistance can develop. 
A
Some multidrug resistant cells that do not express P-glycoprotein have been 
shown to have decreased levels of topoisomerase II, an enzyme involved in DNA 
unwinding and a target for a number of anticancer agents including etoposide and
doxorubicin (Beck, 1987; Gewirtz, 1991; Morrow & Cowan, 1990; Sinha et al, 
1988). Whether these mechanisms represent different stages along a common 
pathway or distinct pathways is not clear. However, a number of P-glycoprotein 
positive multidrug resistant cell lines also express decreased levels of 
topoisomerase II (Deffie et al, 1989; Liu, 1989; Moscow & Cowan, 1988).
A number of tumour cell lines have been cloned and this has given rise to 
subpopulations of cells with differing biological properties. Clones derived from 
a malignant fibrous histiocytoma cell lines showed markedly different 
morphologies and biological properties in vitro (Kanzaki et al, 1991). However, 
when grown in vivo in nude mice all clones gave rise to tumours with histology 
similar to that of the original tumour. Furthermore, these phenotypic differences 
were lost after culture of the clones for 15 passages. In contrast, clones derived 
from a human bladder cancer cell line maintained differences in vitro for more 
than 40 passages and each gave rise to tumours of unique histologies (Brown et 
al, 1990). When drug resistant cell lines are compared with the parental cell line 
from which they were derived it is often the case that a number of possible 
mechanisms of resistance are identified (Batist et al, 1986; Beck et al, 1989; Danks 
et al, 1987; Ozols et al, 1988; Reeve et al, 1990; Sehested et al, 1987a & b; Sinha 
et al, 1989). This could well be explained by multiple changes occurring within 
the cells. However, it is also possible that the drug resistant cell line contains 
subpopulations, each of which has developed resistance via a different pathway. 
Provided that the growth requirements and doubling times do not differ 
significantly the populations will coexist. This suggestion is supported by the work
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of the Goldenberg group who have isolated cloned cell lines from the P388 
leukaemia cell line and from a doxorubicin resistant variant P388/ADR (Deffie 
et al, 1988; Goldenberg et al, 1986). Clones from the resistant cell line differed 
in a number of aspects including drug sensitivity, drug uptake, glutathione-S- 
transferase activity, and susceptibility to DNA strand breaks.
Clearly, if a drug resistant cell line contains subpopulations with differing 
resistance phenotypes attempts to characterise the cell line in terms of resistance 
mechanisms will be complicated. Since it was apparent that subpopulations exist 
within the multidrug resistant ovarian cell line 2780AD this line was cloned along 
with the drug sensitive parental cell line A2780. The original aim was to isolate 
a pure population from each line to allow detailed studies of the effects of 
verapamil on intracellular drug distribution. However when the clones derived 
from cell line 2780AD were tested for sensitivity to daunorubicin it became 
apparent that the range of sensitivities observed depended on when the clones 
were last exposed to the selecting agent, doxorubicin. This chapter, therefore, 
describes the phenotypic instability of some, but not all subpopulations derived 
from the multidrug resistant ovarian cell line 2780AD. Clones were isolated by 
limiting dilution and drug sensitivity and drug accumulation determined over a 
period of 20 weeks during which time cells were grown in the absence of the 
selecting agent.
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Materials and Methods
Isolation and establishment of clones
Exponentially growing cultures of cell lines A2780 and 2780AD were 
trypsinised and suspended at a density of 4 cells/ml. They were plated out into 
flat-bottomed 96-well plates (200 pl/well) so that each well should contain not 
more than one cell. Wells containing a single cell were identified under a light 
microscope and marked within a few hours after plating. The cells were allowed 
to grow in drug-free medium to form colonies at 37°C in a humidified 2% C 0 2 
atmosphere without changing the medium. Clones were harvested 2 or 3 weeks 
later, depending upon colony size. After microscopical examination to ensure that 
there was only a single colony formed in a given well, individual cell colonies 
were dispersed by trypsinisation and transferred to 24-well plates and 
subsequently to 25-cm2 flasks. Stocks were stored in liquid nitrogen. The clones 
were designated according to the parental cell line, followed by the appropriate 
clone numbers, e.g., A2780/clone-l or 2780AD/clone-2. These are sometimes 
abbreviated as A-l or AD-2 etc.
Clones were grown in the absence of drug unless otherwise stated. 
Population doubling times were determined for each clone as described previously 
(Chapter 2 page 23). Photomicrographs were taken with an inverted phase 
contrast microscope (Olympus CK2; Optical CO., Ltd., Tokyo, Japan) with a 
camera attached (Olympus OM System; Optical CO., Ltd., Tokyo, Japan) and
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using Kodak film (Ektachrome 160T; Kodak Ltd., Herts, England).
Chemosensitivity and drug accumulation
Drug sensitivity was determined by the microtitration assay described in 
Chapter 2 (page 24). The sensitivity for each clone was expressed as the ID50 and 
comparisons of sensitivity were made on this basis. Drug accumulation was 
determined by liquid scintillation counting as described previously (Chapter 2, 
page 27). These measurements were repeated after growth of the clones in the 
absence of drug for various times.
Drug efflux
Drug efflux was determined as described in Chapter 2 (page 28). Clones 
from 2780AD were maintained in drug free medium for 12 weeks and drug efflux 
was determined before and 3 days after a single exposure to doxorubicin (2 \lM) 
for 24 hours. The original parental cell lines (A2780 & 2780AD) were also 
included for comparison.
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Cell sizing
Measurement of cell size was performed as described in Chapter 2 (page 
23). Cell size was expressed as a volume ( pm3) determined by assuming that a 
single cell in suspension in isotonic saline is spherical.
Chromosome analysis
Cells grown in the absence of drug for 12 weeks were exposed to colchicine 
(Demecolcine 0.1 pM; Sigma Chemical Company, Poole, U.K.) at 37°C for 4 hr. 
The drug and medium were removed and the cells were incubated for 20 min in 
a hypotonic solution (KC1, 0.04 M; sodium citrate, 0.025 M). In order to obtain 
a high proportion of cells in metaphase, cells were harvested by gentle shaking. 
The cell suspension was centrifuged at 100 g for 3 min and the supernatant 
discarded. Cells were fixed by addition of ice cold acetic-methanol (1 part glacial 
acetic acid + 3 parts methanol) with constant mixing. The suspensions were 
centrifuged at 100 g for 3 min and the resultant pellets were dispersed by using 
a vortex mixer. Fresh fixative solution was then added while mixing continuously. 
The process of cell fixation was completed by repeating this procedure three 
times. The final pellet of fixed cells was resuspended in 0.5 ml of fixative. 
Approximately 50 pi of this suspension was dropped onto a clean glass slide, air 
dried at room temperature, stained with Giemsa and examined under a light
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microscope (Polyvar, Leica UK Ltd., Milton Keynes, U.K.).
The chromosome number was determined for each spread and 50 spreads 
were examined for each clone. The results are presented as a frequency 
distribution.
Immunocytochemistry
Fixation For immunocytochemistry cells were grown on eight chamber glass 
slides (Lab-Tek, Life Technologies Ltd., Paisley, U.K.). The cells were allowed 
to grow at 37°C for 3 days before staining.
Cytospin preparations of cell line H69LX10 were used as a positive control 
and the wild type cell line A2780 was used as one of the negative controls. Non­
adherent H69LX10 cells were centrifuged at 200 g for 5 min, dispersed and 
resuspended in PBS. The cells were then spun onto clean microscopic glass slides 
in a cytospin centrifuge (Shandon Scientific Co. Ltd., London, U.K.) to give a 
monolayer of cells.
Slides were washed three times in PBS (pH 7.4), fixed in acetone for 10 
min, and air dried at room temperature. The slides were then immersed in Tris 
saline (0.05 M, pH 7.6) for 5 min.
Antibodies A mouse monoclonal antibody C219 (CIS UK Ltd., High Wycombe, 
Bucks, U.K.) which recognises an internal epitope of P-glycoprotein was used as
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the primary antibody at a optimal working dilution of 10 pg/ml. A rabbit anti­
mouse immunoglobulin conjugated to alkaline phosphatase (Dako, High 
Wycombe, Bucks, U.K.) was used as the second antibody, diluted 1/20 in filtered 
normal human serum. As a negative control, C219 was replaced by an irrelevant 
monoclonal antibody (Clonab LN-C, Biotest, U.K.). All subsequent dilutions of 
antibodies were made with Tris buffer (0.05 M, pH 7.6).
Alkaline phosphate substrate solutions Two and half milligrams of Naphthol AS
B1 phosphate (Sigma Chemical Company, Poole, U.K.) was dissolved in 50 pi of 
dimethyl formamide (Sigma, U.K.), in vertical laminar flow conditions, until the 
solution turned clear (Solution A). Solution B was prepared by solubilising 2.5 
mg Fast Red TR salt in 5 ml of Veronal Acetate Buffer in a universal container. 
The buffer was made up as follows:
Sodium Acetate (3 H20 ; BDH Chemicals, U.K.) 0.9715 g
Sodium Barbitone (BDH Chemicals, U.K.) 1.4715 g
Distilled Water 247.5 ml
The buffer solution was adjusted to pH 9.2 with 0.1 N hydrochloric acid (approx. 
2.5 ml) and stored at 4°C away from light.
Solution A and B were mixed together and 100 pi of levamisole (Sigma 
Chemical Company, Poole, U.K.), which is known to inhibit the activity of 
endogenous alkaline phosphatase, was added. The resulting solution was filtered
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(Whatman No 1 filter).
Staining Immunocytochemical staining was performed at room temperature 
in a humidified container. The cells were incubated for 2 hr with the primary 
antibody C219, washed in Tris saline for 5 min and then incubated for 45 min 
with the second antibody conjugated to alkaline phosphatase. They were then 
washed in Tris saline for 5 min and incubated with the alkaline phosphate 
substrate solution for 30 min. Slides were counterstained in Haemotoxylin 
solution for 15 seconds, washed briefly (about 20 seconds) in tap water and 
mounted in a water-based mounting medium, glycergel (Dako, High Wycombe, 
Bucks, U.K.).
For specific blocking of C219 immunostaining, a 15 amino acid peptide 
(WQEALDKAREGTC), kindly donated by Dr Elias Georges (Ontario Cancer 
Research Institute, Canada), was used to block the binding site for C219 on P- 
glycoprotein (Georges et al, 1990). Both H69LX10 and 2780AD cells were 
incubated for one hour under the conditions specified above, with C219 (10 
pg/ml) and the peptide (670 pM, 1000 fold molar excess of C219).
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Results
Drug sensitivity of the clones
Sensitivity to daunorubicinwas determined immediately after establishment 
of clones. At this time they had been grown in the absence of drug for almost 4-5 
weeks. Whereas a slight (less than 2 fold) difference existed between clones of 
A2780, clones from 2780AD varied in sensitivity by up to 5 fold (Table I). Six 
resistant clones and 2 from the parental cell line were selected for detailed 
studies.
Morphology of the clones
There were marked differences in the morphologies of the clones (Plate 
1). For example, whereas small rounded cells were characteristic of clone AD-3 
(Plate 1C), slender and spindle shaped cells were characteristic of AD-2 (Plate 
IB). Clone A-10 consisted of long bipolar cells closely aligned with long axes 
parallel to each other (Plate 1A). While a triangular or rectangular shape was a 
feature of clone AD-8, a mixture of rounded and irregular shaped cells was 
characteristic of clones AD-6, AD-10 and AD-16 (Plate ID). In general, clones 
from A2780 tended to grow in tight cell-to-cell contact whereas clones from 
2780AD grew in loose contact. All the clones retained their characteristic
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ID5o (nM)
Experiment Experiment
Clone 1 2 3 Clone 1 2 3
A-l 7.3 3.5 11.6 AD-1 5400 4460
A-2 6.2 4.6 10.0 AD-2* 2625 1625 2700
A-3 7.2 4.6 8.0 AD-3* 5700 4850 8130
A-4 10.2 6.7 10.7 AD-4 1310 1170
A-5* 6.6 5.5 6.7 AD-5 4800 4260
A-6 6.2 10.4 AD-6* 3000 2220 2590
A -l 6.5 7.7 AD-7 5250 3770
> ■ o * 7.5 10.7 AD-8* 3350 2090 3050
A -ll 7.5 10.3 AD-10* 3075 1695 4080
AD-14 2355 2910
AD-15 5950 4920
AD-16* 7000 5295 5240
AD-17 1710
AD-18 3415 3025
Table I Daunorubicin sensitivities of clones from A2780 (A-) and 2780AD 
(AD-) determined using the MTT assay at within 4 weeks of the establishment 
of the clonal populations. Results are shown for three independent experiments 
and each value is the mean of triplicate plates. Clones selected for detailed 
studies are indicated by an asterisk.
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Plate 1 Morphology of clonal cell lines grown in drug free medium for 12 
weeks. Photomicrographs were taken with Kodak film (Kodak Ektachrome 160T) 
at 10 x objective 3 days after passaging of clones A -10 (A), AD-2 (B), AD-3 (C) 
and AD-16 (D).
morphology when grown in drug free medium for at least 20 weeks.
Doubling times and cell volumes
Population doubling times for cell lines A2780 and 2780AD and their 
cloned subpopulations are shown in Table II. Cell line 2780AD and clones 
derived from this line showed similar doubling times and volumes. The parental 
cell line A2780 had a similar doubling time to 2780AD but was smaller. Two 
clones derived from cell line A2780 differed by a factor of 2 in both cell volumes 
and doubling times.
Modal chromosome count
Figure 1 shows the frequency distribution of chromosome numbers for the 
various clones. The number of chromosomes per spread varied from 43 to 49 
with a modal number of 46 for clones AD-2, AD-6, AD-8 and AD-10. However, 
one of the clones (AD-16) comprised mainly cells with a modal chromosome 
number of 47 and AD-3 was largely composed of a mixture of almost equal 
number of cells having 45, 46 or 47 chromosomes.
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Cell line Volume (inn3) Doubling time (hr)
A-5 640.9 18.5
A-10 1314.7 34.5
AD-2 920.3 29.0
AD-3 854.5 24.5
AD-6 1281.8 27.5
AD-8 1230.0 27.5
AD-10 1314.7 25.0
AD-16 1216.1 27.0
A2780 723.1 24.0
2780AD 1022.7 26.0
Table II Characterisation of clones from A2780 (A-) and 2780AD (AD-). Cells 
were dispersed with trypsin and sized in isotonic saline using an electronic particle 
counter. Cell population doubling time was calculated from daily cell counts in 
triplicate of exponential phase cultures. Cell volume are single measurements 
estimated with a suspension of almost 105 cells/ml. Also shown are results for 
A2780 and 2780AD for comparison.
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Figure 1 Frequency distribution of chromosome counts for clones isolated from 
ceil line 2780AD. Fifty chromosome spreads were examined for individual clones.
94
Effect of growth in drug-free medium on daunorubicin sensitivity of the clones
When drug sensitivities were estimated two weeks after exposure to 
doxorubicin, clones derived from cell line 2780AD all showed similar sensitivities 
to daunorubicin (Fig. 2). A gradual and significant increase (P < 0.001; analysis 
of variance) in drug sensitivity was observed for 4 clones (AD-2, AD-6, AD-8 & 
AD-10) when grown in drug-free medium for up to 12 weeks. In contrast, no 
significant difference (P > 0.05) in overall drug sensitivity of clones AD-3 and 
AD-16 was observed even after 20 weeks growth in drug-free medium. Clones 
AD-2, AD-10 and AD-8 showed a further increase in sensitivity between 12 and 
20 weeks such that the ID50s for these 3 clones were similar to that of clone A-5 
derived from the drug sensitive cell line A2780. At week 20 only 3 of the clones 
derived from 2780AD (AD-3, AD-6 & AD-16) showed an increase in sensitivity 
to daunorubicin when exposed to drug in the presence of verapamil (6.6 pM, 
Table III).
Drug accumulation
Drug accumulation was determined by incubation of cells in daunorubicin 
(1 pM) for one hour. The accumulation was estimated after growth of the clones 
in drug-free medium for various times. All six clones derived from 2780AD 
showed markedly reduced daunorubicin accumulation when compared with the
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original A2780 (Fig. 3). However, when grown in drug-free medium for longer 
than 2 weeks, the amount of drug accumulated increased significantly (P < 0.01) 
with increased time of growth in nonselective conditions for 4 of the clones. In 
contrast, AD-3 and AD-16 showed no change in drug accumulation throughout 
the period of study. There was a 6 - 8 fold difference in drug accumulation 
between clones after growth for 12 weeks in the absence of doxorubicin. This 
difference between clones remains apparent when drug accumulation was 
determined over a 5 hour time course (Fig. 4).
Drug efflux
Daunorubicin efflux was measured in the resistant clones grown for 12 
weeks in the absence of drug. The results are shown in Figure 5 together with 
the results from parental cell lines A2780 and 2780AD for comparison. Cell line 
2780AD had been maintained routinely in the presence of drug, until 3 days 
before use. After the 1 hour loading period in the absence of an energy source, 
cell lines A2780 and 2780AD accumulated similar amounts of daunorubicin. Five 
of the resistant clones showed similar accumulation levels but one clone, AD-16, 
accumulated much less drug. Drug accumulation in clone AD-16 could be 
increased to that of the drug sensitive parental cell line A2780 by incubation of 
the cells with daunorubicin in the presence of an energy source and verapamil (50 
pM, Fig. 6).
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Figure 2 Daunorubicin sensitivity of the clones determined at various times 
after exposure to doxorubicin lor 24 hours (week 0). Sensitivity was assessed bv 
the MTT assav. Points are the mean +_ standard error of 3 observations.
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ID50 (nM)
Clone DNR DNR + Vp MF P
AD-2 12.0 _+_ 5.3 9.6 +.2.2 0.8 > 0.05
AD-3 2340 ± _156 173 +.22 13.5 < 0.001
AD-6 793 ±.6.9 43 +.2.2 18.4 < 0.001
AD-8 3.4 +.0.2 4.5 +.0.10 0.8 > 0.05
AD-10 5.7 +_ 1.2 7.0 +_ 1.0 0.8 > 0.05
AD-16 2390 +_202 169 i  6.9 14.1 < 0.001
A-5 5.4 +_ 1.1 5.9 +.0.7 0.9 > 0.05
Table III Drug sensitivities of clones when exposed to daunorubicin in the 
presence and absence of verapamil (6.6 pM) determined by the MTT assay. 
Clones had been grown in drug free medium for 20 weeks. Values are the mean 
±_ standard error of 3 determinations. Also shown is the sensitivity of clone A-5 
(from A2780) for comparison.
ID50 DNR in the absence of verapamil
Modulation Factor (MF) = ___________________________________
ID50 DNR in the presence of verapamil
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Figure 3 Drug accumulation determined at various times after exposure of the 
clones to doxorubicin for 24 hours (week 0). Cells were incubated in 3H- 
daunorubicin (1 pM) for 1 hour and total cellular drug accumulation was 
determined by scintillation counting. Results for cell lines A2780 and 2780AD 
are shown for comparison. Points are the mean ± _  standard error of 3 
observations.
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Figure 4 Total ccilular daunorubicin content of the clones after incubation with 
H-daunorubicin (1 p.M) for various times. Clones from ceil line 2780AD were 
grown in the absence of drug for 12 weeks before estimation of drug 
accumulation. Resuits are the mean + standard error of 3 observations.
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Figure 5 Drug efflux for ciones from 2780AD estimated after growtn in drug 
free medium for 12 weeks. Cells were ioaded with daunorubicin in glucose free 
Hank's Balanced Salt Solution containing sodium azide (10 miM) for an hour ana 
were then transferred into standard culture medium. Cellular drug content was 
measured using liquid scintillation counting. Results are the mean ±_  standard 
error of 3 observations.
101
200
C
<D </)
r-H
C r-H
o D
o o
I
>0
o
c
N
CO
CO
r H r-H
'D o
r —H s
r-H Q_
O)
o
150
2  100
50
0
] -  Verapamil 
^  + Vp 6 .6 mM 
^  + Vp 50mM
A2780 AD-16
Cell lin e
Figure 6 Total cellular drug accumulation ior clone AD-16 following incubation
of the cells with II-daunorubicin (1.0 mAD lor 1 hour in the presence or absence 
of verapamii. Resuits are the mean +_ standard error of 3 determinations. Also 
shown are results for cell line A2780 for comparison.
1 0 2
Both 2780AD and clone AD-3 showed a marked decrease in accumulated 
drug when incubated for 5 min in the presence of an energy source but in the 
absence of daunorubicin, such that only 18% (2780AD) and 14% (AD-3) of the 
accumulated daunorubicin remained. The amount of drug released by the other 
4 clones was much smaller such that 65 - 80% of the accumulated drug remained 
after 5 min, except for clone AD-16 where this represented 75% of the 
accumulated drug. Very little drug was released by A2780 over the duration of 
the study.
Effect of a single exposure to doxorubicin on drug sensitivity and accumulation 
of the resistant clones
Clones grown for 12 weeks in the absence of doxorubicin were exposed to 
doxorubicin for 24 hours. Measurements were made before and 3 days after drug 
exposure.
The effect of a single exposure to drug on daunorubicin sensitivity is shown 
in Table IV. For comparison, the sensitivity is expressed with respect to the 
sensitivity of a particular clone (A-5) from the sensitive parental cell line. After 
growth for 12 weeks in the absence of doxorubicin the drug sensitivities of 4 of 
the clones have increased such that the resistance factors for these clones had 
decreased by 8.7 fold (AD-2), 4.9 fold (AD-6), 17.3 fold (AD-8) and 8.5 fold (AD- 
10). For the other two clones drug sensitivity was not significantly altered (P >
103
0.05) and similarly the resistance factor was maintained. Exposure to doxorubicin 
for 24 hours decreased the drug sensitivity of all 6 clones such that the resistance 
factor was increased for all clones. For clones AD-3 and AD-16 this increase was 
modest (2.2 & 1.8 fold respectively). However, for the 4 clones that showed an 
increase in drug sensitivity with time in culture the resistance factors increased 
significantly by 14.5 (AD-2, P < 0.001), 7.0 fold (AD-6, P < 0.01), 16.1 fold (AD- 
8, P < 0.001) and 15.8 (AD-10, P < 0.001).
Exposure to doxorubicin had no effect on drug accumulation or drug efflux 
for clones AD-3 and AD-16 (Figs. 7 & 8). In contrast, drug accumulation was 
significantly decreased by 4.1-5.3 fold for the other 4 clones and drug efflux was 
markedly increased during the first 5 minutes of incubation in drug free medium 
(Fig. 8 cf Fig. 5 & Table V).
Relationship between daunorubicin sensitivity and intracellular drug content
Figure 9 shows the drug sensitivity of various clones derived from cell lines 
2780AD and A2780 plotted against intracellular drug concentration. Clones from 
2780AD had been grown in the absence of drug for 2, 4, 6 or 8 weeks. There is 
a clear relationship between drug sensitivity and intracellular drug concentration. 
For clones derived from cell line 2780AD the relationship is similar when 
intracellular drug is expressed as total amount per cell (Fig. 9A) or as a 
concentration calculated from measurements of cell volume (Fig. 9B). In
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contrast, the 2 clones derived from A2780 show the same sensitivity to 
daunorubicin but one accumulates twice as much daunorubicin as the other (Fig. 
9A). This difference is much less marked when the intracellular drug is expressed 
as a concentration (Fig. 9B) since clone A-10 (closed square) is twice the size of 
clone A-5 (closed circle).
Figure 10 shows the relationship between drug sensitivity and intracellular 
drug concentration for clones isolated from cell line 2780AD and grown for 4 
weeks in the absence of drug. For each clone two measurements were made, one 
in the absence of verapamil (open symbols) and one in the presence of verapamil 
(6.6 pM, closed symbols). Verapamil clearly increases the drug sensitivity to a 
greater extent than drug accumulation (Fig. 10 cf Fig. 9).
P-glycoprotein expression
Plate 2 shows expression of P-glycoprotein in cell line 2780AD (A) but not 
in cell line A2780 (B). Staining was completely eliminated by the specific 
blocking peptide (Plate 3A & 3B). After growth for 12 weeks in the absence of 
drug 4 clones derived from the resistant line 2780AD (AD-2, AD-6, AD-8 & AD- 
10) showed patchy staining, with a small number of cells intensely stained while 
others were unstained (Plate 4A). Clones AD-3 and AD-16 showed intense 
staining in all cells (Plate 5A & 5B). After exposure of the clones to doxorubicin 
for 24 hours all clones showed uniform staining (Plate 4B).
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Initial3
12 weeks in 
drug free medium
24 hours 
exposure to DOX
Clone RF RF RF
AD-2 695 ±_ 133 80 jL18 1159 ±.138
AD-3 923 ±_159 618 ± .48 2035 +.310
AD-6 605 ±.61 123 ±_ 15 867 ± _140
AD-8 899 +.27 52 ±_6 835 ± _ 188
AD-10 637 ±_ 64 75 _±9 1182 jL 227
AD-16 1189 ±_ 143 996 +_154 2082 ±.502
A-5 1.0 1.0 1.0
Table IV Resistance factors (RF) for clones grown in drug free medium for 12 
weeks and after exposure to doxorubicin (2 pM) for 24 hours. Drug sensitivity 
was measured using the MTT assay. Values are the mean ± . standard error of 
3 observations. Also shown for comparison are resistance factors derived from 
the first screen (initial) performed immediately after the establishment of the 
clones.
ID50 of AD-clone
RF = ________________
ID50 of A-5
a At this stage clones had been grown in drug-free medium for 4-5 weeks.
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Drug efflux
12 weeks After exposure
Cell line drug free to DOX (24hr) Fold increase
AD-2 27.7 ±.5.8 69.5 ±  1.3 2.5
AD-3 86.3 ± 1 .1 91.1 ± 0 .8 1.1
AD-6 34.5 ± 5 .2 71.8 ± 2 .9 2.1
AD-8 20.5 ± 6 .3 59.5 ± 0 .1 2.9
AD-10 26.8 ± 2 .4 59.4 ±  1.3 2.2
AD-16 75.1 ± 7 .1 79.4 ±  1.2 1.1
A2780 6.3 ± 3 .7
2780AD* 82.1 ± 2 .7
Table V Amount of drug (% of total loaded drug) lost during the first five 
minutes from clonal cell lines. Efflux was measured using liquid scintillation 
counting for clones grown in drug free medium for 12 weeks and after exposure 
to doxorubicin for 24 hours. Values are the mean ±  standard error of 3 
determinations.
* Resistant parental cell line was grown continuously in DOX-containing 
medium until 3 days prior to the assay.
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Plate 2 Immunocytochemical detection of P-glycoprotein with the monoclonal 
antibody C219. Cells were grown in multichamber slides for 3 days, washed in 
PBS, fixed in acetone and stained using an indirect alkaline phosphatase method. 
(A) 2780AD (B) A2780.
Plate 3 Immunocytochemical detection of P-glycoprotein with the monoclonal 
antibody C219. Cytospin preparations were fixed in acetone and stained by an 
indirect alkaline phosphatase method (A). In (B) cells were incubated with C219 
antibody in the presence of a 15 amino acid blocking peptide at a molar excess
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Plate 4 Immunocytochemical detection of P-glycoprotein with monoclonal 
antibody C219 of clonal cell line AD-10. Cells were grown in the absence of drug 
for 12 weeks and then stained before (A) and after (B) exposure to doxorubicin 
(2 pM) for 24 hours.
Plate 5 Immunocytochemical staining of P-glycoprotein with monoclonal 
antibody C219 of clonal cell lines AD-3 (A) and AD-16 (B). Clones had been 
grown in drug free medium for 12 weeks prior to staining.
Cisplatin sensitivity of the cloned cell lines
Cell line 2780AD is about 10 fold resistant to cisplatin when compared 
with the parental cell line A2780 (Chapter 5, Table I, page 135). All six clones 
isolated from cell line 2780AD maintained their resistance to cisplatin over the 
first 8 weeks of growth in the absence of doxorubicin (Fig. 11). A small decrease 
(about 2 fold) in sensitivity to cisplatin was observed by week 20. Only a 2 fold 
range in sensitivity to cisplatin was observed between to different clones.
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Figure i l  Sensitivity ot' the clones derived from cell line 2780AD to cisplatin 
determined at various times after growth in the absence of doxorubicin. Resuits 
are the mean + standard error of 3 observations.
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Discussion
A total of 9 clones were isolated from cell line A2780 and 14 from cell line 
2780AD. Cloned cell lines showed morphological homogeneity on the whole but 
there were marked differences between clones. Clonal populations derived from 
A2780 showed similar sensitivities to daunorubicin with a range of only 1.6 fold. 
In contrast, clonal cell lines isolated from cell line 2780AD showed a range of 
sensitivities from 2 to 17.5 fold, depending on when they were last exposed to 
doxorubicin. Six cell lines were selected from 2780AD for detailed studies. Of 
these 2 maintained their resistance even after growth for 20 weeks in the absence 
of drug. The other 4 showed a gradual loss of resistance and this loss was 
associated with increased drug accumulation and decreased expression of P- 
glycoprotein.
Cell lines A2780 and 2780AD demonstrate marked morphological 
heterogeneity to an extent that is not observed amongst at least 30 human tumour 
cell lines in routine use in the Department of Medical Oncology. Interestingly, 
the cisplatin resistant cell line developed from A2780 does not show this 
heterogeneity. The majority of clones isolated from A2780 and 2780AD showed 
morphological homogeneity and the distinct morphology of each clone was 
maintained for more than 20 weeks in culture. This observation is consistent with 
that of Brown et al (1990) who studied clones derived from a human bladder 
cancer cell line.
Drug sensitivity of the clones was determined immediately after selection
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and expansion and at this stage the cells had been grown in drug free medium for 
4 weeks. Cell line 2780AD is normally maintained in the presence of doxorubicin 
(2 pM) and is only removed from drug for about a week before use in
i
experiments. There was little difference between the drug sensitivities of clones 
isolated from cell line A2780 (Table I). A five fold range in sensitivity to 
daunorubicin was seen between clones isolated form cell line 2780AD (ID50; AD- 
4, 1.2 pM cf AD-3, 6.2 pM). The range was small but consistent between 
experiments. Surprisingly, when the cells were exposed to doxorubicin (2 pM) for 
24 hours the range of sensitivities decreased to only about 2 fold (Fig. 2). This 
suggested that in the absence of the selecting agent the drug sensitivity of some, 
if not all, of the clones was changing. In order to test this hypothesis 6 of the 
clonal cell lines derived from 2780AD were selected for detailed study. These 
were chosen over the range of drug sensitivities observed at initial testing and 
cells with reproducible growth and plating efficiencies were favoured. Only two 
clones were selected from cell line A2780 since these showed little difference in 
drug sensitivity and were required only as control cell lines for comparison.
The six clones selected from cell line 2780AD have similar doubling times 
and cell volumes (Table II). Similar doubling times were expected in order for 
the different subpopulations to be maintained in continuous culture of the original 
cell line 2780AD. However, the two clones studied from cell line A2780 differed 
by a factor of 2 in both doubling times and cell volumes. This observation may 
indicate differences in autocrine growth control between subpopulations in cell 
line A2780 such that both clone A-5 and A-10 respond to a particular growth
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factor but only clone 5 can produce and respond to the factor in an autocrine 
manner (Brown et al, 1990; Burgess, 1989; Luetteke & Lee, 1990).
Clonal cell lines derived from 2780AD were exposed to doxorubicin (2 
pM) for 24 hours and drug sensitivity was determined at various times during 
growth in drug free medium. Two clones (AD-3 & AD^16) maintained their 
resistance to daunorubicin even after growth for 20 weeks in the absence of drug 
(Fig. 2). The other four clones selected from 2780AD showed a gradual increase 
in drug sensitivity over the 20 weeks of study such that the sensitivity of 3 of them 
(AD-2, AD-8 & AD-10) was not significantly different (P > 0.05) from that of 
clone A-5 selected from cell line A2780 (Table III). Verapamil was able to 
sensitise the two clones with stable resistance by 13.5 fold (AD-3) and 14 fold 
(AD-16). Two weeks after exposure to doxorubicin clone AD-6 was about 600 
fold resistant to daunorubicin when compared with clone A-5 derived from the 
parental cell line A2780. After growth for 20 weeks in the absence of drug clone 
AD-6 was only about 150 fold resistant to daunorubicin. However, verapamil was 
able to increase the drug sensitivity of this clone to a greater extent (18 fold) than 
for clones AD-3 and AD-16 (Table III). This is an interesting observation and 
suggests that modulation of drug sensitivity by verapamil is limited and is not 
dependent on the degree of drug resistance present. Previously, it has been 
observed that for verapamil maximal activity is obtained in vitro at a concentration 
of 6-7 pM (Plumb et al, 1990). Increasing the concentration of verapamil to 10 
pM had no further effect on drug sensitivity. Furthermore, the modulation factor 
for doxorubicin sensitivity was about 10 fold in each of 3 multidrug resistant cell
lines even though the cell lines themselves showed resistance factors ranging jfrom 
60 fold to 7400 fold. If as has been suggested verapamil exerts its effects by 
competition for closely related binding sites on P-glycoprotein (Yusa & Tsuruo, 
1989) these observations indicate that it is not a very efficient competitor.
The changes observed in drug sensitivity of the clones isolated from 
2780AD agreed with the alterations in drug accumulation. Thus, clones AD-3 and 
AD-16 which maintained their resistance throughout the period of study also 
maintained a markedly reduced drug accumulation when compared with cell line 
A2780 (Fig. 3). The remaining four clones from cell line 2780AD showed a 
gradual increase in drug accumulation with time such that by week 12 three of the 
clones accumulated almost as much drug per cell as did cell line A2780. Clone 
AD-6 accumulated about half as much drug as A2780 by week 12 and this is 
consistent with the observation that the drug sensitivity of this clone could be 
increased by verapamil at week 20. In order to allow the study of all six clones 
from 2780AD along with the two parental cell lines drug accumulation studies 
were limited to measurements of accumulation at a single time point (1 hour). 
It was shown in Chapter 2 that the profile of drug accumulation with time for cell 
lines A2780 and 2780AD differed. Thus it was possible that the changes observed 
at 1 hour might be explained by an alteration in the profile without any overall 
change in drug accumulation over a prolonged time course. It should be noted 
that the drug sensitivity measurements involved a 24 hour drug exposure. Drug 
accumulation was, therefore, determined over a five hour time course for clones 
that had been grown in drug free medium for 12 weeks. These results showed
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clearly that differences between the clones were observed throughout the time 
course and that accumulation over the first hour is an accurate indication of 
cellular drug accumulation (Fig. 4).
Since alterations in drug sensitivity were closely related to changes in drug 
accumulation the results suggested that four of the clones were losing a functional 
drug efflux pump. This hypothesis was supported by a comparison of drug efflux 
rates for clones grown in drug free medium for 12 weeks (Fig. 5). Only a small 
amount of drug was lost from the 3 most sensitive clones (AD-2, AD-8 & AD-10) 
and there was no significant drug efflux from the drug sensitive cell line A2780 
which does not express P-glycoprotein. Cells were loaded with drug in the 
absence of an energy source and in the presence of azide in order to inhibit the 
activity of the efflux pump. As a result cell line 2780AD and clone AD-3 
accumulated as much drug as did cell line A2780. However, clone AD-3 and 
2780AD lost over 80% of cellular associated drug in the first 5 minutes after 
transfer to drug free medium containing an energy source. Clone AD-16 was 
unusual in that at the end of the 1 hour loading point it had accumulated only 
about a third as much drug as the other cell lines studied. This suggests either 
that deprivation of an energy supply did not inhibit the efflux pump in this cell 
line or that drug accumulation is decreased by some other mechanism such as 
increased exocytosis (Sehested et al, 1987a & b). In contrast, if verapamil was 
added during the loading period drug accumulation was increased to that of the 
drug sensitive cell line A2780 (Fig. 6). This observation appears to contradict the 
suggestion that verapamil is maximally effective at 6-7 pM as a resistance
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modulator. However it is not known what effect verapamil has on drug sensitivity 
when cells are exposed to drug and verapamil (50 pM) for 1 hour only. A 24 
hour exposure to verapamil at 50 pM is toxic to the cells (J.A. Plumb personal 
communication).
As expected, P-glycoprotein was clearly detected by immunocytochemistry 
in cell line 2780AD and in clones AD-3 and AD-16 even after growth in the 
absence of drug for 12 weeks (Plate 5). In contrast, after 12 weeks only patchy 
staining was observed in the other four clones derived from 2780AD (Plate 4). 
Thus it appears that these four clones become more sensitive to daunorubicin due 
to a gradual loss of P-glycoprotein. Furthermore, exposure to doxorubicin (2 pM) 
for 24 hours induced P-glycoprotein expression and restored the resistance of the 
clones (Plate 4, Table IV) to greater than that observed after initial selection. 
The expressed P-glycoprotein was clearly functional since drug accumulation was 
markedly reduced (Fig. 7) and drug efflux increased (Fig. 8, Table V).
In Chapter 3 evidence was presented which indicated that there is an 
inconsistency between the effects of verapamil on drug sensitivity and the 
magnitude of the associated effects on drug accumulation. This inconsistency is 
further demonstrated here. When the drug sensitivity of the clonal cell lines 
grown for 2, 4, 6 and 8 weeks in drug free medium is plotted relative to the 
intracellular drug content a clear relationship exists (Fig. 9). There is an apparent 
discrepancy for the two clones isolated from cell line A2780 when cellular drug 
is expressed as pmoles/106 cells. However, if the cell volume is taken into 
account and drug content is expressed as a molar concentration the discrepancy
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is accounted for (Fig. 9A cf 9B). In contrast, when the drug sensitivity of clones 
determined in the presence and absence of verapamil (6.6 pM) is plotted relative 
to intracellular drug content the relationship is lost (Fig. 10). Verapamil clearly 
increases drug sensitivity to a much greater extent than expected for the apparent 
increase in drug content, it should be noted that the drug accumulation 
measurements were made with a fixed extracellular drug concentration of 1 pM. 
Schuurhuis et al (1989) were able to demonstrate a relationship between drug 
sensitivity and drug accumulation with verapamil when drug accumulation studies 
were carried out at the respective ID50 drug concentration.
Cell line 2780AD is cross resistant to cisplatin. This resistance does not 
appear to be related to P-glycoprotein expression since the clones derived from 
2780AD retained their resistance to cisplatin for 8 weeks and showed only a small 
increase in sensitivity by week 20 (Fig. 11).
It is not known why two of the clones retain P-glycoprotein expression in 
the absence of the selecting agent yet four clones do not. It has been suggested 
that in the absence of selection pressure resistant cells may "back-mutate" (Conter 
& Beck, 1984) due to a high reversion rate of the mutations associated with 
resistance (Courtenay & Robins, 1972). In the absence of a detailed cytogenetic 
analysis of the resistant cell line 2780AD it is not known if this is relevant to this 
study. However, the fact that a single exposure to doxorubicin can induce P- 
glycoprotein expression in the clones derived form 2780AD but not in A2780 
suggests that this is unlikely. Cell line 2780AD has a modal chromosome number 
of 47 whereas that for cell line A2780 is 46 (I.F.D. Stephens, personal
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communication). It is interesting to note that the four clones with unstable 
resistance have modal chromosome numbers of 46 whilst clone AD-16 has a 
modal chromosome number of 47 and for clone AD-3 there is range from 45 to 
47. The significance of this observation is not known. It is possible that clones 
AD-3 and AD-16 would in time lose P-glycoprotein expression but that the time 
course for these two clones is much longer than for the other four clones studied. 
Clinical observations would suggest that it is the stable resistance reflected by 
these two clones that is relevant to the failure of chemotherapy. Relapse often 
occurs more than 3 months after chemotherapy and can occur after 2 to 3 years 
(Kaye, 1990). If the initial chemotherapy either induces or selects the resistant 
population then resistance is maintained over a period of months in the absence 
of the selecting agent.
In summary, cell line 2780AD contains subpopulations that differ in the 
stability of their multidrug resistance phenotype. The stability or otherwise of the 
resistance phenotype appears to be caused by differences in the stability of the 
induced expression of P-glycoprotein, the drug efflux pump.
Part of this work was presented at the British Association for Cancer 
Research meeting in Manchester in April 1991 (Luo et al, 1991).
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CHAPTER 5
Effect of polyunsaturated fatty acids on the drug sensitivity of 
cell lines resistant to cisplatin or doxorubicin
Introduction
Several studies have suggested that changes in plasma membrane structure 
and lipid composition are associated with the development of drug resistance 
(Perterson et al, 1983; Rintoul & Center, 1984; Wheeler et al, 1982). The degree 
of structural order of plasma membrane lipids was found to be higher in 
doxorubicin resistant P388 murine leukaemia cells than in sensitive parental cells 
(Ramu et al, 1983a) and a correlation between cell membrane fluidity and 
resistance to doxorubicin was observed in a series of Sarcoma 180 sublines 
(Siegfried et al, 1983). Furthermore, the differences in the lipid composition of 
the cell membrane was also noted between a human ovarian cancer cell line and 
a cisplatin resistant variant (Mann et al, 1988), and this was shown to account, in 
part, for decreased cellular drug accumulation.
Biological membranes are composed of a lipid bilayer in which proteins 
are associated to form a mosaic (Stryer, 1988). Membrane lipids are mostly in 
the form of phospholipids, sphingolipids and cholesterol. The non-polar fatty acyl
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side chains form a hydrophobic interior core relatively impermeable to the 
unregulated movement of substances into and out of the cell.
Membrane fluidity is determined by the degree of unsaturation of the fatty 
acid residues in the phospholipids and by the cholesterol content. Cholesterol 
decreases membrane fluidity by interfering with the orderly packing of the lipids’ 
fatty acid side chains. In higher plants and animals, the predominant fatty acid 
residues are those of the C16 and C18 species palmitic, oleic, linoleic and stearic 
acids. Fatty acids with less than 14 or more than 20 carbon atoms are 
uncommon. Over one half of the fatty acid residues of plant and animal lipids 
are unsaturated, /.e., contain double bonds, and are often polyunsaturated, i.e., 
contain two or more double bonds. Saturated fatty acids are highly flexible 
molecules because there is relatively free rotation about each of their carbon- 
carbon bonds. Fatty acid double bonds almost always have the cis configuration 
and this puts a rigid 30° bend in the hydrocarbon chain that interferes with their 
efficient packing to fill space. The melting point of fatty acids decreases with 
their degree of unsaturation. Similarly, lipid fluidity increases with the degree of 
unsaturation of the component fatty acids. Obviously, the fluidity of biological 
membranes is one of their important physiological properties since it determines 
the ability of the associated protein to move and interact, e.g., receptors, ATPases 
and ion channels (Spector & Bums, 1987). Fluidity will also influence membrane 
permeability and this is particularly relevant to many cytotoxic drugs which are 
thought to enter the cell by passive diffusion such as doxorubicin and cisplatin 
(Siegfried et al, 1985; Andrews & Howell, 1990).
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In animals a variety of unsaturated fatty acids may be synthesised by 
combinations of elongation and desaturation reactions. However, since palmitic 
acid is the shortest available fatty acid in animals and since animals lack delta 12 
desaturases, the delta 12 double bond of linoleic acid cannot be produced. 
Linoleic acid is thus an essential fatty acid (EFA) that must be supplied in the 
diet mainly from plants. Linoleic acid is metabolised to gamma-linolenic acid 
(GLA) and arachidonic acid, the precursor for prostaglandins synthesis (Fig. 1). 
Eicosapentaenoic acid (EPA) and docosahexaenoic acid are also essential fatty 
acids and are found in abundance in fish oils (Murro, 1983). These differ from 
EFAs derived from linoleic acid in the position of the terminal double bond 
relative to the methyl end of the fatty acid. This bond is in position 6 in linoleic 
acid and position 3 in alpha linolenic acid, and fatty acids in the two groups 
cannot be interconverted.
The composition of the cell membrane is, therefore, determined to a 
significant extent by the composition of the diet. A diet rich in polyunsaturated 
fatty acids (PUFAs) can increase the proportion of PUFAs in the cell membrane 
(Awad & Spector, 1976). Similarly, the proportion of PUFAs in the membrane 
of cells grown in culture can be increased by supplementing the culture medium 
with specific PUFAs (Guffy et al, 1984). Since cytotoxic drugs must enter the cell 
to exert their effects it is possible that alteration of the membrane composition 
will alter drug sensitivity. Furthermore, alteration of membrane fluidity could 
influence the activity of membrane components of signal transduction pathways.
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n-3 s e r ie s
Linolenic acid 
(9, 12-Octadeca- 
dienoic acid)
Y-linolenic acid 18:3n-6 
(6,9,12-Octadeca- 
trienoic acid)
n-6 s e r i e s  
18:2n-6
A -6-desaturase
18:4n-3
18:3n-3 “- l in o len ic  acid 
(9,12,15-Octadeca- 
trienoic acid)
Dihomo-Y-lino- 
lenic acid
n-320:3n-6 20:
A -5-desaturase
Aracnidonic acid 20:4n-6 20:5n-3 Eicosapentaenoic acid
(5,8,11,14-Eiccsa- 
tetraenoic acid)
Adrenic acid 22:4n-6 22:5n-3
A -4-desaturase
(5,8,11,14,17-Eiccsa- 
pentaenoic acid)
22:5n-6 22:6n-3 Docosahexaenoic acid
Figure 1 Relationships between two series of polyunsaturated fatty acids and 
between their metabolism bv three desaturase enzymes.
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This is particularly relevant to sensitivity to both doxorubicin and cisplatin since 
alterations of protein kinase C activity have been shown to alter sensitivity to both 
drugs (Basu et al, 1991; Fine et al, 1988; Isonishi et al, 1990).
Such an approach to modulation of drug sensitivity is not related to the 
multidrug resistance phenotype and could therefore apply to drug outwith the 
multidrug resistance phenotype such as cisplatin. Drug accumulation changes 
have been observed in cisplatin resistant cell lines (Bungo et al, 1990; Waud, 
1987), but it is not known how important this is to the mechanisms of cisplatin 
resistance when compared with changes in recognition and removal of cisplatin- 
DNA adducts (Andrews & Howell, 1990). Verapamil does not modulate 
sensitivity to cisplatin but the dihydropyridine calcium channel blocker nifedipine 
does (Onoda et al, 1989). It is possible that nifedipine acts via calcium channels 
since cisplatin resistance has been shown to correlate with changes in calcium 
channels in the lipid and protein-lipid fraction of membranes (Vassilev et al, 
1987). Changes in the lipid composition of the cell membrane could also 
influence these calcium channels and hence sensitise cells to cisplatin.
In the study described in this chapter both GLA and EPA have been used 
in an attempt to modulate sensitivity to cisplatin and doxorubicin. These two fatty 
acids were chosen partly through their availability and topicality (GLA is a major 
component of evening primrose oil), but also because they have been shown to 
have selective toxicities towards tumour cells in their own right! (Beck et al, 1991).i
Numerous studies have shown that certain polyunsaturated fatty acids have 
direct antineoplastic effects in vitro. A total of 30 different human malignant cell
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lines derived from 19 different organs have been shown to be killed effectively by 
PUFAs under conditions that are not lethal to normal animal or human cells 
(Begin et al, 1985; 1986a & b; Booyens et al, 1984). Furthermore, tumour cells 
vary in their sensitivities to various PUFAs (Abou et al, 1988; Begin et al, 1986b; 
Begin & Ells, 1987; Karmali et al, 1985; Sircar et al, 1990). Of the PUFAs tested 
gamma linolenic acid, dihomogamma-linolenic acid, arachidonic acid and 
eicosapentaenoic acid are the most effective agents that show differential toxicity. 
More significantly, PUFAs have been shown to reduce the growth of human 
breast and melanoma and murine Ehrlich tumour xenografts in nude mice 
(Pritchard et al, 1989, Pritchard & Mansel, 1990; Zhu et al, 1989).
The initial study was designed to confirm that GLA and EPA are toxic to 
tumour cells and to determine a non-toxic concentration for use in the modulation 
studies. The ovarian cell line A2780 and the two drug resistant variants 2780AD 
and 2780CP were used for the majority of the work. In order to determine 
whether multidrug resistant cells were also resistant to the toxic effects of PUFAs 
the breast cell line MCF7 and the doxorubicin resistant subline MCF7/Adr were 
also used. Modulation studies were designed to determine firstly whether there 
is a direct interaction between PUFAs and cytotoxic drugs and secondly, whether 
incorporation of the PUFAs into the fatty acids of the cell alters the sensitivity of 
tumour cells to cytotoxic drugs. It has been shown that docosahexaenoic acid can 
sensitise a cisplatin resistant human small cell lung cancer cell line to cisplatin 
(Timmer-Bosscha et al, 1989). In this study cells were grown in the presence of 
the PUFAs for 72 hours with the PUFA replaced after 48 hours. This protocol
resulted in incorporation of the PUFA into cellular phospholipids and was 
therefore chosen for use in these experiments.
Since the PUFAs are cytotoxic agents it was essential in the analysis of the 
results to determine the nature of any interaction between the PUFAs and the 
cytotoxic drugs. Results were analysed by the isobologram method of Steel and 
Peckham (1979) which can discriminate between additive and supra-additive 
(synergistic) interactions. This method has been used previously in the 
department to demonstrate the supra-additive interaction between doxorubicin 
and resistance modulators such as verapamil and quinidine (Plumb et al, 1991).
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Materials and Methods
Cell lines
The three ovarian cancer cell lines (A2780, 2780AD and 2780CP) and the 
two breast cancer cell lines (MCF7 and MCF7/Adr) were used. The cisplatin 
resistant variant (2780CP) of A2780 was obtained from Dr R. F. Ozols (Fox 
Chase Cancer Centre, Philadelphia, U.S.A.) and was maintained in drug free 
medium since resistance to cisplatin of this line was stable for up to 6 months.
The growth conditions for routine maintenance of these cell lines are 
described in Chapter 2.
Polyunsaturated fatty acids
The three polyunsaturated fatty acids (PUFAs), gamma-linolenic acid 
(GLA), eicosapentaenoic acid (EPA) and the lithium salt of gamma-linolenic acid 
(LiGLA), were provided by Scotia Pharmaceuticals (Scotia Pharmaceuticals Ltd., 
Surrey, U.K.). Both GLA and EPA were supplied as oils while LiGLA was a 
powder. The purity of GLA, EPA, and LiGLA was 99%, 90% and 99%, 
respectively.
The PUFAs were solubilised in absolute ethanol and sterilized by filtration 
(Millex-GS, Millipore Ltd., Watford, Herts, U.K.) at a stock concentration of 80
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mg/ml. Aliquots were placed in amber-glass bottles, purged with nitrogen gas 
and the bottles were capped and stored at -70°C in the dark.
All the dilutions were made with complete culture medium immediately 
before use such that the final concentrations of ethanol did not exceed 0.2%.
Cisplatin (Sigma Chemical Company, Poole, U.K.) was prepared just 
before use at a concentration of 1 mM in saline and filter sterilised.
Cytotoxicity assay
Cytotoxicity was determined by the microtitration assay described in 
Chapter 2. The PUFAs were added either before or during drug exposure as 
specified. For exposure periods of up to 48 hours the PUFAs were not replaced. 
In experiments where cells were exposed to PUFAs for 72 hours prior to the 
cytotoxic drug, addition of PUFAs commenced 24 hours after plating out the cells 
and the PUFAs were replaced after 48 hours. Control wells were exposed to 
ethanol (0.2%). For all the experiments cells were allowed to recover in drug 
free medium for 3 days after removal of the cytotoxic drug.
Cells were exposed to the cytotoxic drug (doxorubicin or cisplatin) for 24 
hours in the presence of PUFAs or following a 4 hour pre-exposure to PUFAs. 
For pre-exposure periods of 24 hours or more the drug exposure time was 
reduced to 4 hours in order to prevent cells reaching confluence in the wells 
during the course of the extended assay time.
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I so hologram analysis
Since PUFAs are cytotoxic agents in their own right, the interaction 
between PUFAs and cytotoxic drugs was interpreted by isobologram analysis 
according to the method described by Steel and Peckham (1979).
The index of cytotoxicity used in this analysis was the ID50 concentration 
and for each drug this value was normalised to 1.0. Thus half the ID50 
concentration is 0.5. For drugs with additive toxicity 50% cell kill can be obtained 
by a combination of half the ID50 concentration of drug A and half the ID50 
concentration of drug B (Fig. 2A). The diagonal broken line joins the 
combinations of drugs A and B that will give 50% cell kill if their toxicities are 
additive. If cell kill is greater than 50% the points will lie to the left of this line 
and the interaction is classed as supra-additive. If cell kill is less than 50% the 
points will lie to the right of the line and the interaction is classed as antagonistic. 
The broken line represents additivity for ideal drugs with linear dose response 
curves. Where the dose response curve is non-linear a given increment of drug 
will have a different cell kill depending on the position on the dose response 
curve (Fig. 2B). As a result, an envelope of additivity is constructed that takes 
into account both extremes of the dose response curves of the two drugs.
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Statistical analysis
All the data were subject to statistical analysis using non-paired Student’s 
t test with Minitab Data Analysis Software (Release 7.1--Standard version, 
Minitab, Inc., 1989). Only statistically significant differences are identified.
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Figure 2 (A) Schematic isobologram of the interaction between two drugs A
and B. The ID<0 concentrations are normalised to 1.0. The diagonal broken line 
joints the combinations of drug A and drug B that wall give 50% cell kill if their 
toxicities are additive. (B) For drugs with non-linear dose response curves the 
percentage of ceil kill for a given increment of drug (x) will vary depending upon 
the position on the curve (a cf b). As a result, an envelope of additivity is 
constructed that takes into account both ends of the dose response curve.
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Results
Cytotoxicity of polyunsaturated fatty acids
The sensitivity of three ovarian cell lines to PUFAs is shown in Table I. 
Also shown is the toxicity of doxorubicin and cisplatin for comparison.
The doxorubicin resistant cell line 2780AD was approximately 800 fold 
resistant to doxorubicin and the cisplatin resistant cell line 2780CP was about 19 
fold resistant to CDDP when compared with the parental cell line A2780. Cell 
line 2780AD was aboutllfold cross resistant to CDDP but 2780CP was not cross 
resistant to doxorubicin.
Both 2780AD and 2780CP were cross resistant to all three PUFAs. 
However, the resistance factors were only 2.5 to 4.5 fold. The PUFAs were 
equally cytotoxic with a maximum difference in ID50 concentration of 2 fold in cell 
line A2780 (Table I). Steep dose response curves were obtained for all three 
PUFAs (Fig. 3A, 3B & 3C).
In contrast, the breast cell line MCF7/Adr was about 560 fold resistant to 
doxorubicin, but was more sensitive (P < 0.05) to all three PUFAs than the 
parental cell line MCF7 (Table II). Again the three PUFAs were equally 
cytotoxic within a cell line (Fig. 4A & 4B).
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ID50 (pM)
A2780 2780AD 2780CP
GLA 72.9 ± 4 .3 267.6 ±_2.9*** 327.9 ±_ 2.5***
EPA 94.9 ±.2.0 208.3 ±.11.6** 326.3 ±_9.6**
LiGLA 147.8 +.9.9 301.4 ±.2.1** 229.2 ±.8.2**
DOX 0.003 jL 0.0003 2.350 ±_ 0.100 0.003 ±_ 0.0003
CDDP 0.266 ±_ 0.017 3.080 ± . 0.208 5.080 ±_ 0.950
Table I Sensitivities of human ovarian carcinoma cell line A2780 and its 
doxorubicin (2780AD) and cisplatin (2780CP) resistant variants to polyunsaturated 
fatty acids, doxorubicin and cisplatin determined using the MTT assay. Cells were 
exposed to the individual agents for 24 hours. Values are the mean +_ standard 
error of triplicates and are representative of at least 2 determinations showing 
showing similar results. Asterisks represent the significant difference from control 
A2780 in statistics (Student’s t test; * P < 0.05, ** P < 0.01, *** P < 0.001). 
The abbreviations used are: GLA, y-linolenic acid; EPA, eicosapentaenoic acid; 
LiGLA, lithium salt of y-linolenic acid; DOX, doxorubicin; CDDP, cisplatin.
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ID50 (pM)
MCF7 MCF7/Adr
GLA 265.8 +.30.5 156.3 ±.6.3*
EPA 275.4 +_ 15.9 191.1 ±_5.3*
LiGLA 263.7 ±_ 12.4 200.8 ±_ 11.0*
DOX 0.08 +.0.01 44.9 ±_ 1.1
Table II Sensitivities of human breast cancer cell line (MCF7) and its 
doxorubicin resistant derivative (MCF7/Adr) to polyunsaturated fatty acids and 
doxorubicin determined using the MTT assay. Cells were exposed to the 
individual agents for 24 hours. Values are the mean +_ standard error of 
triplicates and are representative of 2 or more observations showing similar 
results. See Table I for statistical difference and abbreviations.
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Figure 3 Dose response curves for polyunsaturated fatty acids in cell lines 
A2780 (A), 2780AD (B) and 2780CP (C). Cells were exposed to y-linolenic acid 
(GLA), eicosapentaenoic acid (EPA) and the lithium salt of GLA (LiGLA) for 
24 hours, grown in drug free medium for 3 days and cell number was estimated 
by MTT reduction. Cell survival (absorbance) is expressed as a percentage of the 
absorbance of control untreated wells. Points are the mean jL standard error of 
triplicate plates.
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MCF7 (A) and MCF7/Adr (B). See Figure 3 legend for details.
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Sensitivity of ovarian cell lines to cisplatin and doxorubicin when exposed in the 
presence of PUFAs
Since A2780 was more sensitive to PUFAs, lower concentrations were 
applied to this cell line. The concentrations of PUFAs used for the two resistant 
cell lines in all studies were within a range not exceeding 40 jig/ml (GLA, 
143.7 pM; EPA, 132.2 pM; LiGLA, 142.1 pM) at which no significant inhibition of 
cell growth was observed after a 24 hour exposure (Fig. 3A & 3B).
The lithium salt of GLA had no effect on the sensitivity of all 3 cell lines 
to cisplatin (Table III). EPA had no effect on the platinum sensitivity of A2780 
and 2780AD but increased slightly the sensitivity of 2780CP at all concentrations 
used and this increase was just significant (P < 0.05). The lowest concentration 
of GLA used (A2780, 2.5 pg/ml; 2780AD and 2780CP, 10 pg/ml) had no effect 
on platinum sensitivity. However, higher concentrations produced a significant 
decrease in the ID50 in A2780 (P < 0.01) and 2780AD (6 fold, P < 0.001). For 
2780CP the increase in sensitivity was only just significant at the highest 
concentration of GLA used (40 pg/ml, P < 0.05). It should be noted that all ID50 
are calculated using a control absorbance value obtained from cells that were not 
exposed either to cisplatin or to PUFAs.
A 24 hour co-exposure to PUFAs and doxorubicin had no effect on the 
sensitivity of any of the 3 cell lines to doxorubicin (Table IV).
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i d 50 ( hM)
A2780 2780AD 2780CP
CDDP 0.49 ±.0.08 5.03 ±.0.30 10.52 +.0.57
+ GLA(9.0) 0.36 ±_ 0.05 (35.9) 4.67 ±_ 0.28 12.20 +.0.75
+ GLA(18.0) 0.13 ± . 0.04** (71.8) 3.02 +.0.26** 9.37 ±_ 0.49
+ GLA(35.9) 0.06+.0.01** (143.7) 0.82+.0.15*** 6.13 +.0.81*
+ EPA(8.3) 0.46 +.0.06 (33.0) 6.20 +.0.50 8.33 +.0.46*
+ EPA(16.5) 0.60 ±_ 0.05 (66.1) 3.90 ±.0.73 8.00 ±.0.30*
+ EPA(33.0) 0.40 +_ 0.02 (132.2) ND 8.10 J i  0.97*
+ LiGLA(8.9) 0.60 +_ 0.07 (35.5) 3.40 ±_ 0.48 11.53 ±.0.83
+ LiGLA(17.8) 0.29+.0.02 (71.1) 3.62+.0.49 10.30 ±_ 0.27
+ LiGLA(35.5) 0.27 ±_ 0.03 (142.1) 5.15 +.0.69 11.90 ±.0.50
Table III Sensitivities of wild type (A2780), doxorubicin (2780AD) and cisplatin 
(2780CP) resistant human ovarian carcinoma cell lines to cisplatin measured using 
the MTT assay. Cells were exposed to drug for 24 hours in the presence or 
absence of polyunsaturated fatty acids (PUFAs). Values are the mean ±_ standard 
error of triplicates and are representative of 2 observations showing similar 
results. The figures in parentheses represent the concentrations of individual 
PUFAs ( pM). Asterisks represent statistically significant difference from control, 
Le.y cisplatin alone (see Table I). ND, not done.
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ID30 ( HM)
A2780 2780AD 2780CP
DOX 0.007 ±.0.0003 4.62+.0.28 0.014 ±_ 0.0004
+ GLA(9.0 pM) 0.008 +.0.0005 (143.7 pM) 4.92 ±_ 0.37 0.012 ±.0.001
+ EPA(8.3 pM) 0.006 0.0003 (132.2 pM) 3.83+.0.15 0.008 ±.0.002
+ LiGLA(8.9pM) 0.007 ±_ 0.0008 (142.1 pM) 4.87 +.0.22 0.011 ±_ 0.003
Table IV Sensitivities of wild type (A2780), doxorubicin (2780AD) and cisplatin 
(2780CP) resistant human ovarian cancer cell lines to doxorubicin (DOX) in the 
presence or absence of polyunsaturated fatty acids (PUFAs) assessed using the 
MTT assay. Values are the mean ±_ standard error of triplicates and are 
representative of 2 determinations showing similar results. Figures in parentheses 
represent the concentrations of PUFAs used. See Table III legend for details.
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Effect of pre-exposure of cells to PUFAs on the cytotoxicity of cisplatin and 
doxorubicin
A four hour pre-exposure of the 3 cell lines to PUFAs had little effect on 
sensitivity to either doxorubicin or cisplatin (Table V). A small increase (1.4 fold) 
in the sensitivity of 2780AD to doxorubicin when exposed to EPA (132.2 pM, 40 
pg/ml) was only just significant (P < 0.05). Similarly, all three PUFAs produced 
a small increase (1.2-1.3 fold) in the sensitivity of 2780CP to cisplatin and this 
increase was only just significant (P < 0.05).
The effects of a 24 hour and 48 hour pre-exposure to PUFAs on the 
sensitivity of the 3 cell lines to doxorubicin and cisplatin are shown in Tables VI 
and VII respectively. The most significant effects were seen in cell line 2780CP. 
A 48 hour pre-treatment with GLA (40 pg/ml, 143.7 pM), EPA (40 pg/ml, 132.2 
pM), and LiGLA (40 pg/ml, 142.1 pM) sensitised 2780CP to cisplatin by 8, 10 
and 11 fold respectively (P < 0.001, Table VII). This effect was also apparent, 
but less marked after exposure to PUFAs for 24 hours (Table VI). A 48 hour 
pre-treatment with GLA, EPA, and LiGLA sensitised 2780CP to doxorubicin by 
3.5, 6 and 4 fold respectively (P < 0.01, Table VI).
Pre-exposure to PUFAs for up to 48 hours had little effect on the 
sensitivities of A2780 and 2780AD to cisplatin or on the sensitivity of A2780 to 
doxorubicin (Tables VI & VII). The sensitivity of 2780AD to doxorubicin was 
significantly increased by pre-exposure to GLA (2.5 fold, P < 0.01), EPA (22 fold, 
P < 0.001) and LiGLA (2.6 fold, P  < 0.01) for 48 hours (Table VII). This trend
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was also apparent after 24 hour pre-exposure but only significant for EPA (9 fold, 
P < 0.01, Table VI).
Studies of prolonged pre-treatment of the cells with PUFAswere confined 
to the most significant interactions observed in the shorter pre-exposure periods. 
Furthermore, the concentration of the PUFA was reduced in an attempt to avoid 
excessive toxicity of the PUFA itself. Pre-exposure to GLA for 72 hours 
sensitised 2780CP to cisplatin by 5.5 fold (GLA, 35.9 |iM; P < 0.01) and 315 fold 
(GLA, 71.8 pM; P < 0.001; Table VIII). Pre-exposure to EPA for 72 hours 
sensitised 2780AD to doxorubicin by 6.5 fold (EPA, 33 jiM; P < 0.01) and 17 fold 
(EPA, 66.1 pM; P < 0.001; Table VIII).
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ID;„ ( nM)
A2780 2780AD 2780CP
DOX 0.003 +.0.0003 2.350 ±.0.100 0.003 +_ 0.0003
+ GLA(9.0) 0.002 ±.0.0006 (143.7) 2.180 ±.0.115 0.003 +_ 0.0002
+EPA(8.3) 0.003 ±_ 0.0004 (132.2) 1.710 ±.0.110* 0.003 ±_ 0.0002
+ LiGLA(8.9) 0.003 ±.0.0004 (142.1) 2.320 ±.0.087 0.004 ±_ 0.0003
CDDP 0.187 ±.0.005 1.367 ±_ 0.027 5.180 ±.0.087
+ GLA(9.0) 0.163 ±.0.012 (143.7) 1.390 ±.0.049 4.450 +_ 0.115*
+ EPA(8.3) 0.245 +.0.013 (132.2) 1.090 ±_ 0.087 3.860 ±_ 0.104*
+ LiGLA(8.9) 0.229 +.0.010 (142.1) 1.570 ±.0.081 4.380 ±.0.162*
Table V Sensitivities of wild type (A2780), doxorubicin (2780AD) and cisplatin 
(2780CP) resistant human ovarian carcinoma cell lines to doxorubicin (DOX) or 
cisplatin (CDDP) measured using the MTT assay. Cells were exposed to PUFAs 
for 4 hours and then to DOX or CDDP alone for 24 hours. Values are the mean 
±_ standard error of triplicates and are representative of 2 observations showing 
similar results. Figures in parentheses represent concentrations ( pM) of PUFAs 
used for A2780 and the two derivatives, respectively. Asterisks represent 
statistically significant difference (see Table III legend for details).
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ID50(pM)
A2780 2780AD 2780CP
DOX 0.050 ±.0.006 15.70 +_ 0.60 0.156 ±.0.03
+ GLA(9.0) 0.032 J l 0.001 (143.7) 9.77 ±_ 1.38 0.045 ±.0.005
+ EPA(8.3) 0.038 ±_ 0.002 (132.2) 0.17^0.01*** 0.070 +.0.011
+ LiGLA(8.9) 0.029 Jl 0.005 (142.1) 13.93 +.0.97 0.154 ±.0.032
CDDP 1.73 +.0.13 18.00 +. 1.79 50.83 ±_ 1.42
+ GLA(9.0) 1.19 +.0.11* (143.7) 25.90 :L 5.87 9.13 ±.0.54**
+ EPA(8.3) 1.15 ±.0.07* (132.2) 13.70 jL 0.56 35.13 +_ 2.02*
+ LiGLA(8.9) 1.14 +.0.12* (142.1) 33.67 ±_ 2.59* 19.03 ±.2.66**
Table VI Sensitivities of wild type (A2780), doxorubicin (2780AD) and cisplatin 
(2780CP) resistant human ovarian carcinoma cell lines to doxorubicin (DOX) or 
cisplatin (CDDP) measured using the MTT assay. Cells were exposed to 
individual PUFAs for 24 hours and then to DOX or CDDP alone for 4 hours. 
Values are the mean ±_ standard error of triplicates and are representative of 2 
observations showing similar results. Figures in parentheses represent the final 
concentrations (pM) of PUFAs used for A2780 and the two derivatives, 
respectively. Asterisks represent statistically significant difference (* P < 0.05, 
** P < 0.01, *** P < 0.001).
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i d 50 ( hM)
A2780 2780AD 2780CP
DOX 0.022 ±  0.001 8.87 ± 0 .5 2 0.080 ±0 .006
+ GLA(9.0) 0.016 ±.0.003 (143.7) 3.48 ±0.16** 0.023 ±  0.004**
+ EPA(8.3) 0.018 ±  0.004 (132.2) 0.39 ±0.11*** 0.013 ±0.002**
+ LiGLA(8.9) 0.020 ±.0.002 (142.1) 3.42 ±0.78** 0.020 ±  0.003**
CDDP 0.79 ±.0.01 13.20 ± 0 .4 6 26.77 ± 0 .8 2
+ GLA(9.0) 0.50 ±.0.06* (143.7) 19.07 ±  1.68 3.32 ±1.05***
+ EPA(8.3) 0.65 .±0.14 (132.2) 8.70 ±  1.72 2.68 ±0.59***
+ LiGLA(8.9) 0.41 ±0.03** (142.1) 14.67 ±  1.89 2.43 ±0.34***
Table VII Sensitivities of wild type (A2780), doxorubicin (2780AD) and 
cisplatin (2780CP) resistant human ovarian carcinoma cell lines to DOX or 
CDDP measured using the MTT assay. Cells were exposed to individual PUFAs 
for 48 hours and then to DOX or CDDP alone for 4 hours. Values are the mean 
±  standard error of triplicates and are representative of 2 observations showing 
similar results. Figures in parentheses represent the final concentrations ( pM) of 
PUFAs used for A2780 and the two derivatives, respectively. Asterisks represent 
statistically significant difference (* P < 0.05, ** P < 0.01, *** P < 0.001).
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ID50( hM)
2780AD 2780CP
+ EPA Doxorubicin + GLA Cisplatin
0 16.40 +_ 2.16 0 56.67 +_ 7.69
33.0 pM 2.53 +_0.44** 35.9 pM 10.33 +_4.05*
66.1 pM 0.95 +.0.15*** 71.8 pM 0.18 +.0.02***
Table VIII Cellular sensitivities of doxorubicin resistant (2780AD) and cisplatin 
resistant (2780CP) cell lines to doxorubicin and cisplatin following a 72 hour pre­
exposure of cells to either eicosapentaenoic acid (EPA) or y-linolenic acid 
(GLA). EPA or GLA was added to the cells on day 1 and day 3 after plating, at 
the final concentrations indicated. The cells were subsequently exposed to either 
doxorubicin or cisplatin for 4 hours in the absence of PUFAs. Values are the 
mean ±_ standard error of triplicates and are representative of 2 determinations 
using the MTT assay. Asterisks represent significant differences (Students’ t test; 
* P < 0.05, ** P < 0.01, *** P < 0.001).
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Effect of PUFA pre-exposure alone on cell survival
Although non-toxic concentrations of the PUFAs were chosen from the 
original dose response curves (Fig. 3A, 3B & 3C) it was apparent in the pre- 
exposure experiments that these concentrations were toxic and that the toxicity 
increased with prolonged exposure time. This is shown in Figures 5, 6 and 7. In 
Figure 5A the dose response curves for 2780CP pre-exposed to PUFAs for 24 
hours are plotted with cell survival expressed as a percentage of control where the 
control contained the relevant concentrations of the PUFA. Figure 5B shows the 
dose response curves plotted with cell survival expressed as absorbance at 570 nm. 
It is clear that even at very low cisplatin concentrations significant cytotoxicity is 
observed and this is due to the PUFA alone. This toxicity is much more marked 
after a 48 hour (Fig. 6A & 6B) and 72 hour (Fig. 7A & 7B) pre-exposure to the 
PUFAs.
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Figure 5 Dose response curves for cell line 2780CP. Cells were pre-exposed to 
GLA, EPA or LiGLA for 24 hours before exposure to cisplatin for 24 hours. Cell 
survival was measured 3 days later by MTT reduction. Points are the mean +_ 
standard error of triplicate plates. In (A) cell survival is expressed as a 
percentage of the absorbance of control wells. For cisplatin alone the controls 
were not exposed to cytotoxic drug. For experiments where cells were p re­
exposed to PUFAs the controls were exposed to the PUFAs alone. In (B) cell 
survival is expressed as the absorbance per well.
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152
I so hologram analysis
The interaction between PUFAs and the cytotoxic drugs was interpreted 
by isobologram analysis. Figure 8A shows the concentrations of cisplatin and 
GLA which when combined for 24 hours produce a 50% reduction in cell 
survival. The dotted line delineates the envelope of additivity. It is clear that the 
majority of points lie within the envelope indicative of an additive interaction. 
Figure 8B shows the isobologram for the interaction between GLA and cisplatin 
when cells were exposed to GLA for 24 hours before exposure to cisplatin for 24 
hours alone. Again the interaction appears to be additive. Isobolograms could 
not be constructed for the other interactions studied since only one PUFA 
concentration was used.
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Discussion
These results show clearly that the polyunsaturated fatty acids (PUFAs), 
Le.t gamma-linolenic acid and eicosapentaenoic acid, are cytotoxic to tumour cell 
lines. Surprisingly, the doxorubicin and cisplatin resistant ovarian cell lines were 
cross resistant to the PUFAs although the resistance factors were much smaller 
than those for the selecting agent. Cross resistance to PUFAs was not a general 
feature of MDR cell lines since the doxorubicin resistant breast cell line showed 
a tendency towards greater sensitivity to PUFAs than the parental cell line. 
PUFAs were shown in some cases to sensitise the cells to cytotoxic drugs. 
However, when the drug interactions were analysed by the isobologram method 
the interactions were clearly additive and not supra-additive or synergistic.
The cisplatin and doxorubicin resistant sublines of the ovarian cell line 
A2780 showed steep dose response curves to both GLA and EPA with no 
apparent toxicity below 100 pM (Fig. 3B & 3C). Although A2780 was only 2.5 
to 4.5 fold more sensitive to the PUFAs the dose response curve was less steep 
and toxicity was observed at concentrations of only 10 pM. 2780CP is 19 fold 
resistant to cisplatin and 2780AD is 800 fold resistant to doxorubicin (Table I). 
Although both resistant lines are cross resistant to the PUFAs the resistance 
factors are low compared to those of the cytotoxic drug against which resistance 
was developed. In order to confirm whether cross resistance to PUFAs is a 
feature common to all multidrug resistant cell lines the breast cell line MCF7 and 
its doxorubicin resistant subline MCF7/Adr was included in the study. The
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doxorubicin resistant variant MCF7/Adr was shown to be slightly more sensitive 
(P < 0.05) than its parental cell line MCF7 to all three PUFAs (Table II). This 
suggests that the resistance observed for the ovarian cell lines is a specific feature 
of the lines and not a general phenomenon. The difference may relate to the fact 
that the parental cell line A2780 is highly sensitive to a number of cytotoxic drugs 
(J.A. Plumb, personal communication) and could thus be hypersensitive to the 
effect of the PUFAs.
These results are consistent with previous studies which have shown that 
PUFAs have direct antineoplastic activities and that tumour cell lines differ in 
their sensitivities to PUFAs (Abou et al, 1988; Karmali et al, 1985). The 
mechanisms by which PUFAs kill tumour cells is unknown but there is evidence 
that toxicity may be related to lipid peroxidation and production of superoxide 
radicals (Begin et al, 1986a, 1988; Das et al, 1987; Das, 1990). This is supported 
by the observation that the toxicity of GLA in human neuroblastoma cells in vitro 
is inhibited by antioxidants (Fujiwara et al, 1984). The most cytotoxic PUFAs 
appear to be those with 3, 4 or 5 double bonds and these include EPA and GLA. 
Docosahexaenoic acid which has 6 double bonds was much less toxic to cells 
(Begin et al, 1986a). Furthermore, EPA and GLA are more potent in terms of 
lipid peroxidation and superoxide radical formation than docosahexaenoic acid. 
Part of the selective toxicity of PUFAs to tumour cells might be explained by 
altered activities of enzymes that metabolise PUFAs. Both delta 6- and 5-fatty 
acyl-CoA desaturases have been shown to be impaired or absent in some tumour 
cell lines (Howards & Howard, 1974; Maeda et al, 1978).
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Initial studies of the interaction between PUFAs and cisplatin and 
doxorubicin were designed to determine whether there is an acute effect of 
PUFAs on cellular drug sensitivity. The ovarian cell lines were used for these 
studies since both doxorubicin and cisplatin resistant variants were available. Co­
incubation of cells with PUFAs and cisplatin had varying effects on cell survival 
depending on the cell line and the PUFA used. The most significant interactions 
were observed between GLA and cisplatin (Table III). Since A2780 was more 
sensitive to the PUFAs than the two resistant sublines it was necessary to use 
lower concentration of the PUFAs for A2780 than were used for 2780CP and 
2780AD in these experiments. A range of concentrations were used that 
produced less than 10% cell kill alone. GLA sensitised all three cell lines to 
cisplatin and the effect was dose dependent (Table III). This combination was, 
however, least effective in the cisplatin resistant cell line 2780CP. In contrast, 
EPA had no effect on the sensitivity of cell lines A2780 and 2780AD to cisplatin 
but produced a slight decrease in the ID50 concentration of cisplatin in cell line 
2780CP (1.3 fold, P < 0.05, Table III). None of the PUFAs had any effect on the 
doxorubicin sensitivity of the three cell lines (Table IV). The results of these 
experiments were not very promising and it was not possible to increase the 
concentration of the PUFAs without a significant increase in the toxicity of the 
PUFAs themselves.
In an attempt to enhance the sensitising effects of the PUFAs cells were 
pre-incubated with the PUFAs before exposure to the cytotoxic drugs. The 
rational behind this approach was based on the assumption that pre-treatment
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with the fatty acids would have one of two effects. Either they would make the 
cells more sensitive to subsequent exposure to a second cytotoxic agent or pre­
exposure would allow the fatty acids to be incorporated into cellular lipids and 
thus alter membrane fluidity. A four hour pre-exposure had little effect on either 
doxorubicin or cisplatin sensitivity in any of the three cell lines (Table V). 
Exposure to PUFAs for 24 hours before exposure to cisplatin was less effective 
for 2780AD than the co-exposure (Tables III & VI). However, it should be noted 
that for this experiment the exposure time to cisplatin and doxorubicin was 
reduced to 4 hours and this may well explain this difference. Alternatively, it 
could be that the PUFA and cytotoxic drug interact in some way that requires 
their joint presence.
A 48 hour pre-treatment period had marked effects on the sensitivity of 
2780CP to both cisplatin and doxorubicin (Table VII). Both EPA and GLA were 
equally effective (10 and 8 fold sensitisation respectively, P < 0.001) and there 
was no difference between the two formulations of GLA. This was surprising 
since GLA was more effective than EPA or the lithium salt of GLA when a 24 
hour pretreatment period was used (5.6 fold cf 1.4 and 2.7 fold respectively, Table 
VI). All three fatty acids sensitised both 2780AD and 2780CP to doxorubicin 
when cells were pre-treated for 48 hours with the PUFAs (P < 0.01, Table VI).
In order to ensure that the PUFAs would be incorporated into cellular 
phospholipids the protocol used by Zijlstra et al (1987b) and Timmer-Bosscha et 
al (1989) was followed. They used docosahexaenoic acid which is less cytotoxic 
than EPA or GLA. Cells were exposed to the fatty acid on days 1 and 3 after
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plating such that the overall exposure time to PUFAs was 72 hours before 
exposure to cisplatin for 4 hours. Lipid analysis revealed significant incorporation 
of the docosahexaenoic acid into cellular lipids (Timmer-Bosscha et al, 1989; 
Zijlstra et al, 1987b). For the 72 hour pre-treatment experiments the 
concentration of the fatty acid was reduced but the fatty acid was replaced after 
48 hours. The stability of EPA and GLA in culture medium is not known so the 
exact exposure time may not be 72 hours. Only the interaction between EPA and 
doxorubicin in 2780AD and GLA and cisplatin in 2780CP were examined and the 
results were consistent with the trends already observed for the shorter pre­
exposure periods. However, these experiments also showed clearly that part if not 
all of the apparent sensitisation was due to the toxicity of the fatty acid alone 
(Fig. 7B). Thus at the highest concentration of GLA used for pre-treatment of 
2780CP the fatty acid alone killed more than 50% of the cells and it was not 
possible to determine an ID50 concentration for cisplatin. If cell survival is 
expressed as a percentage of the control where the control for GLA exposure is 
cells exposed to GLA for 72 hours, it is possible to compare treatments. 
However, the parameter derived from this approach is not an ID50. It is assumed 
that the effect of GLA alone on cell survival is constant regardless of the 
concentration of cisplatin used. Clearly when studying the interaction of two 
drugs it would be wrong to assume that GLA increases cisplatin toxicity but not 
vice versa.
Since the toxicity of the fatty acid alone was apparent in all pre-treatment 
experiments (Figs. 5, 6 & 7), drug interactions were subject to a more critical
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analysis. The isobologram method described by Steel and Peckham (1979) was 
originally designed for studies of the interaction between radiation and cytotoxic 
drugs (Steel, 1979) and it has been used successfully to study interactions between 
two agents (Carter & Wampler, 1986; Church et al, 1988; Gessner, 1988; Plumb 
et al, 1991). Application of this method of analysis to the interaction between 
GLA and cisplatin showed clearly that the two agents demonstrate additive 
toxicities (Fig. 8) since the majority of points lie within the envelope of additivity. 
This is entirely consistent with previous reports that PUFAs can sensitise drug 
resistant cell lines to cytotoxic drugs (Timmer-Bosscha et al, 1989; Zijlstra et al, 
1987b). Zijlstra et al (1987b) showed that the doxorubicin resistant cell line 
GLC4/ADR was more sensitive to docosahexaenoic acid than GLC4 and was 
sensitised to doxorubicin by 72 hour pre-treatment with the PUFA, whereas the 
parental cell line GLC4 was not sensitised. Similarly, docosahexaenoic acid 
sensitised cisplatin resistant subline GLC4CP to cisplatin but did not sensitise 
parental cell line GLC4 to cisplatin (Timmer-Bosscha et al, 1989). They were 
unable to explain this sensitisation since cellular platinum concentration, total 
DNA bound platinum and the amount of the major DNA-platinum adducts 
increased in both cell lines. The sensitisation could well be explained if GLC4CP 
like G LQ /A D R is more sensitive to docosahexaenoic acid than GLC4.
One of the aims of this study was to determine whether incorporation of 
PUFAs into the membrane could alter membrane permeability and thus alter 
drug permeability. However, the PUFAs themselves were more toxic than 
anticipated and this aim was not achieved. Several studies have suggested that
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this may be a worthwhile approach (Ramu et al, 1983a; Siegfried et al, 1983). 
More recently, there have been a number of reports suggesting that alteration of 
protein kinase C activity can alter platinum sensitivity (Basu et al, 1991; Hofmann 
et al, 1988; Isonishi et al, 1990). Protein kinase C migrates to the cell membrane 
when activated. Alterations of the membrane composition could therefore alter 
protein kinase C activity and hence cisplatin sensitivity.
These results suggest that EPA and GLA do not have a role as resistance 
modulators in drug resistant cells. However, additive toxicities can be of value 
in the clinic provided that the toxicities of the drugs to normal tissues are non­
additive. High concentrations of PUFAs have been given to both animals and 
man without apparent toxicity (Siegel et al, 1987; Van der Merwe, 1984; Van der 
Merwe et al, 1987; Zhu et al, 1989). Since it is known that tumour cells derive 
most of their fatty acids from the host circulation it should be possible to deliver 
PUFAs to tumour cells, perhaps preferentially. This aspect has already been 
exploited in attempts to reduce the cachexia associated with the growth of some 
tumours (Beck et al, 1991).
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CHAPTER 6
General Discussion
On the whole the aims of this thesis have been achieved. These aims
were:
(2) to characterise verapamil as a resistance modulator
(2) to determine whether verapamil affects intracellular drug distribution
(5) to find alternative means of overcoming drug resistance
The results contribute to an understanding of both the mechanisms by which
tumours develop resistance to chemotherapeutic agents and the strategies to
overcome such resistance.
Although verapamil has limited value as a resistance modulator in the
clinic, it is one of the most potent agents identified in vitro and its activity was
shown to include cell lines that do not overexpress P-glycoprotein (Chapter 2
Table I). This observation is significant in itself since it suggests that verapamil
has more than one mechanism of action in terms of drug sensitisation.
Furthermore, the two other resistance modulators studied, quinidine and bepridil,
could only modulate the sensitivity of cell lines that express very high levels of P-
glycoprotein. This observation was not followed up; however, subsequent studies
suggested a possible explanation.
Both the human P-glycoprotein positive multidrug resistant cell lines
showed a marked reduction in drug accumulation when compared with the
parental drug sensitive cell lines. Sensitisation by verapamil was accompanied by
an increase in drug accumulation but the degree of sensitisation was much greater
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than was expected on the basis of the increased drug accumulation. This 
discrepancy refers to total drug accumulation per cell as measured by incubation 
of cells in labelled drug followed by scintillation counting. The technique of 
autoradiography allowed discrimination between drug located in the nuclear and 
cytoplasmic compartments. These studies revealed that in both drug sensitive and 
drug resistant cell lines the majority of the drug as revealed by grain counts was 
present in the nucleus. However, the ratio of nuclear to cytoplasmic grains was 
greater in the drug sensitive cell lines than in the drug resistant cell lines (Chapter 
3 Tables I-IV). Verapamil not only increased the total grain count per cell in the 
drug resistant cell lines but increased the nuclear to cytoplasmic grain count ratio 
to equal that of the drug sensitive cell lines. These observations confirm 
suggestions that verapamil can alter intracellular drug distribution. It was 
however clear that by autoradiography only a fraction of the total accumulated 
drug was studied, probably due to loss of free drug during fixation of the cells. 
When drug distribution was observed by autofluorescence of daunorubicin there 
was clearly a large pool of drug in the cytoplasm yet very few grains were present 
in the cytoplasm of either the drug sensitive or drug resistant cell lines. The 
increase in grain count caused by verapamil in the human multidrug resistant 
ovarian cell line 2780AD (8 fold) was closer to the degree of sensitisation 
observed (13 fold) than that of the overall 2 fold increase in drug accumulation 
observed by scintillation counting of whole cells. It is therefore tempting to 
suggest that autoradiography detects the pool of drug that is closely linked with 
cellular cytotoxicity whereas other techniques detect all pools of drug.
There was a noticeable difference between the cellular handling of 
doxorubicin and daunorubicin. Although these are closely related molecules they 
have very different spectra of antitumour activities. The difference in drug 
accumulation between A2780 and 2780AD was 4 fold for doxorubicin but 16 fold 
for daunorubicin. This could be explained if daunorubicin is a better substrate 
for the drug efflux pump than doxorubicin. Recently, it has been proposed that 
P-glycoprotein is a ‘flippase’ molecule (Higgins & Gottesman, 1991). For this 
model, substrate specificity would be determined by the ability of the molecule 
to intercalate into the lipid bilayer of the cell membrane. Since daunorubicin is 
more lipophilic than doxorubicin (Arcamone, 1985; Gewirtz & Yanovich, 1987) 
it may intercalate into the membrane more efficiently and may thus be a better 
substrate for a ‘flippase’.
It would be interesting to use autoradiography to study drug accumulation 
in the human non-small cell lung cancer cell lines investigated in this thesis. 
Verapamil was able to modulate the sensitivity of the four cell lines, yet only one 
had detectable levels of mdrl mRNA. Although the effect of verapamil on drug 
distribution was observed in cell lines with high levels of P-glycoprotein, it is 
possible that this effect is not related to P-glycoprotein. To date only one study 
has identified P-glycoprotein in an intracellular location (Willingham et al, 1987) 
and it is not obvious how a protein in the cell membrane could directly affect 
drug distribution between the nucleus and cytoplasm. If verapamil caused a 
redistribution of drug in the non-small cell lung cancer cell lines, this would 
explain the effects on drug sensitivity and provide evidence that P-glycoprotein is
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not involved.
One of the most interesting studies observed in this thesis arose from an 
observation made during the studies of drug distribution. Both of the two ovarian 
cell lines contained cells of markedly different morphologies. Furthermore, the 
amount of drug accumulated by the cells related to their morphology. For the 
drug sensitive human ovarian cell line A2780 differences in drug accumulation 
were related to cell size. Two clonal cell lines were isolated from cell line A2780 
which differed in size by a factor of 2. When drug accumulation was expressed 
as amount per cell, clone A-10 accumulated twice as much drug as clone A-5 yet 
the drug sensitivity of the two clones were similar. However, if cellular drug 
content was expressed as a concentration there was no difference between the two 
clones. Thus it is important to take cell size into account when comparing drug 
content between cell lines.
Six clonal cell lines isolated from the multidrug resistant cell line 2780AD 
were studied in detail. These clones revealed a marked heterogeneity in stability 
of the multidrug resistance phenotype. This was an unexpected finding since it 
was assumed that the chronic exposure to doxorubicin would have been a 
sufficient selection pressure to isolate a fairly homogeneous subpopulation. Two 
of the clones maintained their resistance phenotype even in the absence of drug 
whilst the other four showed a gradual decline in resistance with increasing time 
in culture in drug free medium. Loss of resistance was shown to be associated 
with a loss of P-glycoprotein expression. However, even when drug sensitivity had 
reverted almost to that of the drug sensitive cell line, resistance and P-
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glycoprotein expression could be reinduced by a single 24 hour exposure to 
doxorubicin. This observation suggests that the clonal cell lines retain the 
background of a resistance phenotype but that this requires constant exposure to 
the selecting agent to maintain a functional resistance phenotype. The relevance 
of these observations to clinical drug resistance is not clear. However, it is 
generally assumed that if P-glycoprotein is a significant factor in clinical drug 
resistance, relapsed tumours will express P-glycoprotein. By analogy with the 
clonal cell lines it is possible that the relapsed tumour is indeed a resistant 
subpopulation selected by the first course of chemotherapy but which does not 
necessarily express P-glycoprotein in the absence of exposure to the cytotoxic 
drug. However, the first course of chemotherapy would be sufficient to reinduce 
P-glycoprotein expression.
The use of polyunsaturated fatty acids to modulate drug sensitivity was a 
novel and rather unusual approach. It was not therefore surprising that these 
studies failed to demonstrate any evidence of modulation. However, a number 
of interesting observations did emerge. The polyunsaturated fatty acids were 
quite toxic in their own right and this toxicity has been shown elsewhere to be of 
potential use in the selective killing of tumour cells (Begin et al, 1985, 1986a & 
b; Booyens et al, 1984). Because of this toxicity it was difficult to determine 
whether the drug interactions observed were additive or synergistic and 
isobologram analysis proved highly effective in distinguishing between these two 
possibilities. The toxicities of the polyunsaturated fatty acids were clearly additive 
with respect to both doxorubicin and cisplatin and the polyunsaturated fatty acids
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were equally effective in the drug sensitive parental cell line and in the 
doxorubicin resistant and cisplatin resistant cell lines. Since polyunsaturated fatty 
acids have been administered to patients without any undue side effects (Dodge, 
1990; Van der Merwe et al, 1987) it is possible that they could be used in addition 
to standard chemotherapy in order to enhance tumour cell kill. Clearly, studies 
in a human tumour xenograft model would be well worthwhile pursuing.
Concluding remarks
The importance of P-glycoprotein in clinical drug resistance is not clear 
and it is certainly not the only mechanism involved. However, in those tumour 
types where P-glycoprotein is expressed to any significant degree, studies with 
resistance modulators are well worth attempting. Verapamil may not be suitable 
for use in the clinic, but the studies described in this thesis show that it has 
properties that are not shared by all modulators and indeed may be able to 
modulate in the absence of P-glycoprotein. This is an interesting property that 
could have significant value to the understanding of mechanisms of drug 
resistance. Perhaps more importantly the use of polyunsaturated fatty acids in 
combination with chemotherapy should be recommended since this approach 
appears to be effective against very different mechanisms of drug resistance.
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